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RA and SLE are B cell-mediated autoimmune diseases dominated by 
autoantibodies that affect over 1.5 million Americans. Together RA and SLE contribute 
to over 29 billion in healthcare costs, therefore due to the high financial burden and 
physical toll of these diseases on the population, there is a critical need to effectively and 
efficiently diagnose and treat RA and SLE patients. The aim of our studies was to 
identify biomarkers and drug targets to improve the identification and treatment of RA 
and SLE patients. As discussed above, APRIL, BAFF and TSLP have been implicated in 
the pathogenesis of RA and SLE. Current therapeutics used to treat RA and SLE provide 
sub-optimal response in a third of patients treated. Therefore, identifying subsets of 
patients based on their surface and soluble biomarkers and identifying which therapeutics 
that will provide the most benefit for these patient cohorts has the potential to rationalize 
the treatment of RA and SLE patients. The cytokine APRIL has been implicated as a 
potential disease mediator in B cell mediated autoimmune diseases. Our studies show that 
surface APRIL is expressed on circulating myeloid cells and on total CD19+ B cells and 
correlates with increased disease in RA patients. Our findings suggest that surface APRIL 
could provide an easily detectable biomarker and be a useful selection criterion for the 
 xii 
administration of drugs that antagonize APRIL. Another cytokine, TSLP has been 
implicated in the pathogenesis of RA. We found that TSLP was elevated in the synovial 
fluid of RA and in the plasma of SLE patients compared to non-inflammatory OA 
patients indicating that TSLP may act locally in the joints of RA patients and 
systemically in SLE patients. These studies provide insight into the role of APRIL and 
TSLP in B cell mediated autoimmune diseases and provide a rationale to guide treatment 
strategies based upon the expression of APRIL and TSLP. This work is significant 
because it has the potential to provide clinicians with easily accessible biomarkers to 
identify the best treatment plan to target these cytokines and their function in pathways 
involved in RA and SLE pathogenesis. 
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CHAPTER ONE 
INTRODUCTION 
The role of the immune system is to detect and destroy foreign antigens while 
discriminating non-self from self-antigens.  Tolerance mechanisms are used to prevent 
the recognition of self-antigens, however when these mechanisms breakdown 
autoreactive cells emerge.  In autoimmune disease, the detection of autoantibodies, is an 
indication of the breakdown in negative selection and the presence of autoreactive B cells 
(1). The development of autoimmune disease is multifaceted with possible genetic and 
environmental (bacterial or viral infection and smoking) contributions that eventually 
lead to the breakdown of tolerance mechanisms and the release of autoreactive cells into 
circulation. The genetic risk factors and environment triggers for the two most common 
autoimmune diseases—rheumatoid arthritis (RA) and systemic lupus erythematous (SLE) 
are diagramed in Figure 1 (reviewed in (2-5). 
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Figure 1: Genetic and Environmental Risk Factors in RA and SLE. RA only risk 
factors are in black font, SLE only risk factors are in purple font and shared factors are 
indicated by bolded black font.  
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B cell Mediated Autoimmune Disease 
RA and SLE are B cell-mediated autoimmune diseases dominated by 
autoantibodies that recognize self-antigens (6, 7). These autoantibodies cause chronic 
systemic immune responses that result in debilitating pain and multi-organ damage (8). 
As B cells develop and differentiate into antibody-producing plasma cells, they can be 
stimulated to proliferate and/or survive at different stages in the process by secreted pro-
survival cytokines (9-11).  The same factors that propagate the inflammation in 
autoimmune disease also have the potential to lead to further disease as an increased risk 
of diffuse large B cell lymphoma is associated with RA and SLE (12, 13). 
 
Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a systemic B cell-mediated autoimmune disease 
dominated by autoantibodies that recognize self-antigens (6, 7). These autoantibodies 
result in chronic systemic immune responses that target the synovium, cartilage, and bone 
resulting in joint damage (8). During inflammatory synovitis, immune cells infiltrate the 
joint (14) and produce cytokines. Many types of immune cells are involved in the joint 
inflammation including monocytes, dendritic cells (DCs), B cells and T cells and 
fibroblast like cells within the joint. RA synovial tissue samples reveal an increased 
frequency of immune cells with T cells having the highest frequency followed by B cells, 
macrophages and DCs having the lowest frequency (14) suggesting that these immune 
cells are involved in RA joint damage or they are upstream mediators of the 
inflammatory cascade that leads to damage. B cells are stimulated by these cytokines at 
different stages of development to proliferate and differentiate into antibody-producing 
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plasma cells, thus continuing the cycle of chronic inflammation in RA (9-11). Further 
evidence of the pathogenic role of these immune cells can be seen in untreated patients 
diagnosed with early RA who have significantly higher levels of immunoglobulins, 
autoantibodies and clinical markers of inflammation (CRP and ESR) (15). Disease 
activity within these early RA patients correlates with immunoglobulin levels and 
markers of receptor editing further implicating the pathogenic role of B cells in RA (15).  
 
SLE 
Systemic lupus erythematous (SLE) is the second most common autoimmune 
disorder and primarily effects woman of child bearing age (16). In addition, more severe 
forms of SLE and poorer therapeutic responses are observed in patients of Afro-
Caribbean, Native American, Hispanic, and Filipino decent compared to Caucasian 
patients (17).  SLE is characterized by the loss of B cell tolerance and by abnormally 
activated circulating B cells that produce multiple autoantibodies that target nuclear and 
to a lesser extent, cytoplasmic antigens (18, 19). These autoantibodies bind to self-
antigen inducing inflammation and immune complex formation.  Immune complexes 
ultimately lead to tissue damage when the lodge in the small vessels of the kidney, lung 
and skin of SLE patients.  Abnormal proportions of B cell subsets have been observed in 
SLE.  Within SLE patients, the frequency of transitional 2 (T2) B cells, memory B cells 
and plasma cells is increased in comparison with healthy donors (20). These patients also 
have increase serum IgM, IgG, and IgA levels compared to healthy controls likely due to 
increased plasma cells (21). The development of self-antigens in SLE may be due to the 
breakdown in cellular mechanisms of removing apoptotic and necrotic cells that leads to 
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activation of autoreactive B cells.  SLE patient have a reduction in monocytes, 
macrophages and DCs; a reduced phagocytic activity in macrophages, reduced C1q levels 
production of autoantibodies against C1q, which could result in the inability to remove 
the source of self-antigens (22-24). 
 
Immune Cells Involved in RA and SLE Pathogenesis 
B cells 
B cells have been implicated in the pathology of both RA and SLE.  B cells 
contribute through the 1) production of autoantibodies, 2) expression of co-stimulatory 
molecules, 3) expression of adhesion molecules, 4) antigen presentation, 5) production of 
chemokines that induce immune cell infiltration, and 6) secretion of cytokines (reviewed 
in (25, 26).   
 
Normal B cell Development 
In the bone marrow, B cells develop from hematopoietic stem cells (HSCs) 
through a series of sequential steps as shown in Figure 2. Immature B cells emerge from 
the bone marrow, travel through the periphery, and migrate to the spleen for further 
maturation and development.  During the B cell development process, there are several 
stages in which B cells are eliminated due to the inability to signal through their B cell 
receptor or they react strongly to self-antigen. From the pro-B to the pre-B stage, B cells 
acquire the heavy chain of the B cell receptor (BCR). From the pre-B to immature stage, 
they acquire light chains. Cells that do not properly rearrange either their light or heavy 
chain are eliminated. B cells that are autoreactive are removed by negative selection 
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through apoptosis, receptor editing or anergy during the immature stages of B cell 
development (27, 28). Immature B cells travel from the bone marrow through the 
periphery to the spleen where they undergo transitional stages of B cell development. In 
the spleen, deletion of the autoreactive B cells occurs during the transitional one (T1) and 
transitional two (T2) stages (29). Surviving T2 cells become either follicular mature (FM) 
B cells that migrate through the periphery or marginal zone (MZ) B cells that remain 
static in the spleen. Upon activation, these naïve mature B cells will differentiate into 
memory B cells or plasma cells (30-32).  Surface marker expression allows for the 
identification of the stages of B cells development.  All B cells express the surface 
marker CD19 and memory cells are identified based on CD27 surface expression. Naïve 
mature cells are CD19+, CD27-, and IgM+. Naïve mature cells can be further divided 
into B cells subsets based on the co-expression of CD24 and CD38, which allows for the 
identification of transitional B cells (CD24++CD38++), mature B cells (CD24+CD38+) 
and IgM+ memory B cells (CD24+CD38-) (33). 
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Figure 2: Model of Normal B cell Development. B cells are produced through a series 
of sequential steps that begins in the BM with hematopoietic stem cells (HSC).  Immature 
B cells emerge from the bone marrow, travel through the periphery to the spleen were 
these naïve B cells undergo negative selection. It is during the transitional stages (T1 and 
T2) that autoreactive B cells should be removed by negative selection by receptor editing, 
anergy or apoptosis. Surviving T2 cells further differentiate into either follicular 
(circulating) mature or splenic marginal zone B cells. Upon activation, these mature naïve 
B cells will differentiate into memory or plasma cells.  
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B cells in Autoimmune Disease 
B cells function to make antibodies, present antigens, secrete cytokines and 
chemokines, and to generate memory cells to enhance the humoral immune response. 
However, normal B cell functions can be exploited by autoreactive B cells to produce 
pathogenic autoantibodies, and to cause the downstream activation of additional immune 
mediators such as T cells. The presence of autoantibodies in both RA and SLE patients 
indicates a breakdown in negative selection processes. Examination of tolerance 
checkpoints within SLE patients revealed defects in these checkpoints during the 
transitional stages of B cell development (see Figure 2) and in germinal centers (GC) 
allowing autoreactive B cells to differentiate into memory and plasma B cells (34, 35).  
The pathogenic role of B cells in RA was first identified with the discovery of 
rheumatoid factor (RF, auto antibody against constant region of IgG antibodies) and more 
recently through the use of the B cell depletion therapy Rituximab (monoclonal anti-
CD20 antibody) and the identification of anti-cyclic citrullinated peptides (anti-CCP) (26, 
36). Unfortunately, current B cell therapies do not directly target plasma cells due to the 
lack of CD19, CD20, or CD22 expression on these cells, but these long-lived plasma 
cells eventually die and are unable to be replaced due to continuation of B cell mediated 
therapies.  
While T cells have been associated with RA, recent studies have shown that B 
cells are required to activate T cells within the synovium (37). Co-stimulatory molecules 
CD80 and CD86 are highly expressed on B cells from RA and SLE (38). The increased 
expression of co-stimulatory molecules may increase the antigen presenting capability of 
these B cells and produce a more efficient T cell activation. Toll-like receptors (TLRs) 
 9 
also play a role in B cell activation and antibody production in RA and SLE. TLR9 
recognizes hypomethylated DNA, and has been shown to increase dsDNA autoantibody 
production in SLE B cells (39). Immune complexes containing DNA from SLE patient 
serum can also activate this TLR9 mediated cytokine response in B cells depicted in 
Figure 3 (40). 
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Figure 3: Overview of the Role of B cells in Rheumatoid Arthritis and Systemic 
Lupus Erythematous. B cells are pathogenic in RA and SLE by producing 
autoantibodies, presenting antigens, secreting cytokines and chemokines, and by 
generating memory cells and plasma cells to propagate the autoimmune inflammatory 
response. 
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Monocytes 
Three monocytes subsets in human peripheral blood have been identified based 
upon the expression of CD14 and CD16 (FcγRIIIa), and have distinct functional 
properties.  Classical monocytes make up the majority of circulating monocyte 
population express CD14 but lack CD16 expression. These monocytes specialize in 
phagocytosis and the production of reactive oxygen species. Intermediate monocytes 
(CD14+CD16+) express high levels of MHC class II molecules enhancing their antigen 
presentation capability.  Intermediate monocytes also produce the pro-inflammatory 
cytokines TNF-α, IL-1β, and IL-6 when stimulated with LPS. Non-classical monocytes 
have low-level CD14 and high CD16 expression. These monocytes also produce TNF-α, 
express MHC class I molecules, exhibit patrolling behavior and are activated by TLR7 
and 8 ligands making them important mediators during viral infections (41, 42).  
Monocytes that express CD16 (intermediate and non-classical) are considered 
inflammatory based on their production of inflammatory cytokines and high MHC 
expression (43). In addition, immune complexes (ICs) from RA and SLE serum can 
activate FcγRIIIa (CD16) receptors located on monocytes and macrophages leading to the 
production of TNF-α (44). In RA patients, intermediate monocytes from RA synovium 
are able to promote the expansion of Th17 cells in vivo, and the frequency of Th17 cells 
correlated with percentage of CD14+CD16+ monocytes in RA PB (45). In SLE patients, 
monocytes and macrophages show a reduced phagocytic ability, which could lead to an 
accumulation of cellular debris and self antigens (23).  The pro-inflammatory functions 
of intermediate and non-classical monocytes implicate them as cellular mediators in 
autoimmune disease. 
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Dendritic Cells 
 Dendritic cells (DCs) are important antigen presenting cells that survey the body 
for invading pathogens. DCs play an important role in regulating innate and adaptive 
immune responses through the secretion of pro- or anti-inflammatory cytokines and 
chemokines that draw immune cells to the area of inflammation. Once DCs encounter 
antigen, they travel to the lymph nodes where they undergo maturation, upregulate MHC 
class II and co-stimulatory molecules needed to activate T cells and B cells (14, 46). Two 
types of DCs have been identified in humans myeloid DC (mDC) and plasmacytoid DCs 
(pDC) based on surface marker phenotype and their immune functions.  mDCs express 
TLRs 1-6, 8, and 10, while pDCs express TLR7 and 9 (47).  pDC also have an additional 
receptor, CD32, that preferentially binds IgG immune complexes and shuttles these 
complexes to endosomal location of TLR7 and 9.  These TLRs are activated by ssRNA 
and hypomethylated DNA. SLE and RA patients have elevated levels of circulating CpG 
motif rich DNA (48), which has the potential to engage these TLRs on DCs and on B 
cells.  
Studies performed on DCs from systemic autoimmune patients indicate that mDC 
may be more important in the systemic immune response and T cell activation, while 
pDC response occurs mainly in the site of tissue inflammation and result in B cell 
activation. Both populations of DCs have been implicated in the pathology of RA and 
SLE. Increased numbers of both mDCs and pDCs are present in RA patients (49). In the 
blood and synovial tissues of RA patients, mDCs have elevated levels of MHC class II 
and co-stimulatory molecules, and are responsible for T cell priming and the production 
of inflammatory cytokines. pDCs are also found in the synovial tissues and are mainly 
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responsible for increased IFN-α and BAFF production on B cell activation (50). These 
DCs produce BAFF and APRIL (cytokines involved in B cell survival and activation) 
inducing T cell independent B cell production of IgG and IgA antibodies (51). Mouse 
mDCs can ingest apoptotic blebs, which leads to DC maturation, upregulation of co-
stimulatory molecules, production of IL-6 and TNF-α and skewing toward a Th1/Th17 
response (52). In SLE patients, mDC have increased activation, induce the differentiation 
of Th1 and Th17 cells and pDC have been identified in tissue lesions and nephritic 
kidneys. pDCs are increased in RA patient synovium and correlate with anti-citrullinated 
peptide antibody titers (50).    
 
Inflammatory Mediators Elevated in RA and SLE  
The factors contributing to systemic B cell mediated autoimmune diseases are 
multifactorial and involve a complex network of immune cells and inflammatory 
mediators. In our studies, we focus on attention on the inflammatory mediators that 
influence B cell activation and differentiation and the cells involved in their production 
and signaling.  
 
TSLP 
Thymic stromal lymphopoietin (TSLP) is an IL-7 like cytokine that signals 
through the TSLP receptor (TSLP-R). TSLP is primarily produced by epithelial cells in 
the skin, gastrointestinal tract, thymus, and lungs and by immune cells such as DCs, mast 
cells, basophils, and fibroblasts (53-57). TSLP induced signaling requires the 
heterodimeric TSLP-R receptor consisting of an IL-7 receptor alpha (IL-7Rα) subunit 
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and a TSLP-R subunit, and upon activation, signals through the Jak-STAT pathway in 
human cells. TSLP-R is expressed on DCs, NK cells, mast cells, and T and B cells (58).  
The current paradigm of TSLP’s role in inflammation is that it directs a DC 
mediated differentiation of CD4+ T cells into Th2 cells (59). This mechanism of TSLP 
activated DCs inducing a Th2 response is seen in asthma, atopic dermatitis, systemic 
sclerosis, and cancer (56, 60-62). However, recent studies have shown that TSLP may 
also induce a Th17 response in Hepatitis C infected hepatocytes and in atherosclerosis 
(60). These studies suggest that the role of TSLP may differ based on cell type. Recently, 
synovial fibroblast from RA patients have been shown to produce TSLP when stimulated 
with TLR ligands through a NF-κβ mediated pathway (63). TSLP is further implicated in 
RA, as it is elevated in the synovial fluid of RA patients and produced a RA-like disease 
in an RA mouse model (64, 65).   
 
Tumor Necrosis Factor Super Family Members 
Members of the tumor necrosis factor superfamily have been implicated in the 
pathology of multiple autoimmune diseases.  Several TNFSF family members have 
emerged as targets for therapy in the treatment of autoimmune diseases such as SLE.  The 
normal function and role in B cell mediated autoimmune diseases will be discussed 
below. 
 
BAFF 
B cell activating factor (BAFF, Blys, TALL-1, THANK, TNFSF13B and zTNF4) 
is a type II transmembrane protein, expressed as a cell surface protein, and released in its 
 15 
soluble form by proteolytic cleavage by furinase. BAFF protein has multiple biologically 
active forms: membrane-bound and soluble trimers, 20-mers, and 60-mers in humans 
(66). BAFF is the ligand for three receptors BAFF-R, the transmembrane activator, 
calcium modulator, and cyclophilin ligand interactor (TACI) receptor and the B-cell 
maturation antigen (BCMA) receptor. 
Increased BAFF levels lead to increased numbers of B cells in vivo (67) 
indicating that BAFF may be responsible for B cell homeostasis.  Inflammatory cytokines 
promotes B cell production of BAFF (68). In vitro studies show, that BAFF increases cell 
splenic memory B cell survival and recovery following memory B cell activation (69). 
BAFF may be more important for mature autoreactive B cell survival than naïve 
B cells (70) as B cells compete for BAFF for survival and therefore in mice with a 
diverse B cell repertoire autoreactive B cells are competitively eliminated. Autoimmunity 
may develop due to the increased threshold of chronic BCR stimulation that is needed to 
cause negative selection due to elevated BAFF levels (70). Therapeutics that reduce 
BAFF levels may be beneficial in reducing numbers of autoreactive B cells.  Addition of 
exogenous BAFF to normal and SLE B cell cultures enhanced the cell viability in normal 
B cells cultures.  This could be to the increased occupancy of BAFF-R by BAFF in SLE 
thereby preventing further activation by exogenous BAFF (71).  
BAFF has been implicated in the development and maintenance of RA and SLE 
through studies in mouse models of lupus and RA as well as clinical studies. BAFF 
transgenic mice exhibit defects in negative selection of autoreactive transitional T1 cells, 
elevated numbers of mature B cells and develop SLE-like disease where they produce 
anti-dsDNA, rheumatoid factor, and anti-nuclear antibodies (11, 72). B and T cells are 
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increased and the CD4+ cells display a more activated phenotype (73).  Th17 cells, a 
subset of CD4+ T cells are also elevated in mice that overexpress BAFF, and are 
decreased in BAFF knockout mice (73). Local BAFF expression in the joints of the RA 
collagen-induced mouse model (CIA) led to increased Th17 cells production and disease 
activity (74).  BAFF knockout mice have a blockade from the T1 to the T2 B cell 
developmental stage and have reduced autoantibodies (11, 70, 75).  
Soluble BAFF is elevated in SLE and lupus nephritis (21, 76-79). Serum levels of 
BAFF positively correlated with IgG levels in the plasma of SLE patients and with anti-
dsDNA titers (21).  Soluble BAFF positively correlates with SLEDAI (76), CRP levels 
(78) and negatively correlates with blood Hb and IgA levels, (78) and BAFF-R 
expression on CD19+ B cells (76). SLE patients with high disease activity have increased 
levels of BAFF mRNA in total PBMCs and B cells compared with SLE patients with low 
disease activity and healthy donors (20, 68, 77, 78). Patients with higher anti-dsDNA 
antibodies have increased BAFF mRNA expression in CD19+ B cells (20). CD4+ and 
CD8+ T cells from SLE patients express BAFF mRNA (80). In SLE, BAFF mRNA 
levels positively correlated with disease activity (SLEDAI), but did not correlate with 
soluble BAFF (20, 77, 78). However, Lin et al showed that serum BAFF levels positively 
correlates with BAFF mRNA levels in PBMNCs (21).  Elevated BAFF mRNA 
expression correlates with autoantibody positivity (anti-dsDNA and anti-RNP antibodies) 
in SLE patients (68). Synovial tissue sections from patients with severe RA have greater 
BAFF expression than sections from mild RA or OA patients (81). BAFF in SF is higher 
than in serum in RA patients (82). 
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Surface BAFF is present on naïve and memory B cells and plasma cells in SLE 
patients with high disease activity (20). Surface BAFF was identified on CD14+ 
monocytes within the blood and SF of RA patients (82). Surface BAFF is expressed on 
leukemic B cells compared to healthy donors (83). TLR9 can induce expression of 
surface BAFF on human B cells, increased proliferation (84) and can also lead to T cell 
independent antibody production (85). 
 
APRIL 
A proliferation inducing ligand (APRIL, TNFSF13A, TALL-2, TRDL-1) is a 
member of the tumor necrosis factor super family (TNFSF) that is expressed by 
monocytes (86), dendritic cells (87), macrophages (88), neutrophils, myelocytes (86), 
astrocytes (89), adipocytes (90), and activated T and B cells  (91).  The effects of APRIL 
are dependent on the receptor that it binds seen in Figure 4. APRIL has two receptors: 
TACI and BCMA. 
Human APRIL consists of 6 exons that can be alternatively spliced in to 3 mRNAs 
to form APRIL β, γ, and δ, and these splice forms are not present in mouse.  In silico 
studies suggests that APRIL-β and APRIL-δ  isoforms are a membrane bound, 
uncleavable forms of the APRIL protein (66). In addition, an intergenic splice form exists 
that is generated from the combination of exons 1-6 of TWEAK (a closely related family 
member) and exons 2-6 of APRIL producing TWE-PRIL (92). TWE-PRIL has the 
transmembrane domain of TWEAK and the trimeric form of APRIL as an uncleaveable 
membrane bound protein (92).  Alternative APRIL splice forms give rise to surface 
APRIL (66). BAFF protein is known to be cleaved at the cell surface; therefore, surface 
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BAFF is a naturally occurring form of this protein (66).  In contrast, APRIL was found to 
be processed intracellulary within the Golgi apparatus and secreted from the cell (93). 
Surface APRIL has been observed in leukemic B cells, macrophages, and monocytes; 
however, which isoforms of APRIL (or alternatively, TWE-PRIL) led to this surface 
expression has not been determined (82, 83, 94-96). Two APRIL single-nucleotide 
polymorphisms (SNP) on codons G67R and N96S have been identified (97).  The G67R 
polymorphism is shown to be associated with SLE susceptibility in the Japanese (97), 
African-American and Hispanic population (98). 
APRIL has been implicated in the pathogenesis of RA and SLE.  Serum APRIL 
levels were significantly higher in SLE patients compared to RA patients and healthy 
donors (99) while another study showed that APRIL was higher in both RA and SLE 
(79). Discrepancies exist over whether APRIL is higher in the synovial fluid or in the 
serum of autoimmune patients. Initial reports show that APRIL is higher in the SF than in 
the serum of RA patients (82). A more recent study shows that serum levels of APRIL 
were elevated in RA and no difference was seen between APRIL SF samples and normal 
donors (96). Serum APRIL levels negatively correlate with anti-dsDNA antibody titer in 
SLE patients (100). Serum APRIL in SLE correlated with British Isles Lupus Assessment 
Group (BILAG), BILAG musculoskeletal, and BILAG cardiorespiratory score (99). SLE 
patients with high disease activity have increased levels of APRIL mRNA in B cells 
compared with healthy donors and these APRIL mRNA levels positively correlated with 
disease activity determined by SLEDAI (20).  Lupus nephritis glomeruli tissues have 
elevated levels of APRIL and BAFF mRNA compared to healthy donors (101). This 
could potentially be due to infiltrating inflammatory cells into the kidney of SLE patients. 
 19 
APRIL and its receptor BCMA are expressed by fibroblast-like synoviocytes (FLS) in 
RA and not OA synovial tissues. When these cells are treated with exogenous APRIL not 
BAFF increased APRIL mRNA and inflammatory cytokines IL-6, TNF-α, and IL-1β in 
RA FLS and not OA FLS. Treatment of RA FLS cells with BCMA-FC ameliorated these 
effects. APRIL may contribute joint erosion in RA by increasing osteoclast activity 
through increased expression of RANK-L (96).  APRIL is strongly associated with 
DLBCL in RA and SLE patients with the highest APRIL expression seen in tumors from 
SLE and RA patients with high disease activity (102).  These studies indicate that APRIL 
is involved in the local and systemic pathology of both RA and SLE and may contribute 
to further disease development. 
 
BAFF-R 
BAFF-R exclusively binds BAFF and is highly expressed on normal human 
splenic B cells (69) and is present on circulating naïve (CD27-) and resting memory 
(CD27+CD38-)(71). BCR engagement upregulates BAFF-R expression on T2 and 
mature B cells (103). BAFF signaling through the BAFF-R increases B cell chemotactic 
response to the chemokines CCL21, CXCL12, and CXCL13 (104).  BAFF induced 
chemotaxis is mediated through the p38 MAPK pathway (104). This BAFF/BAFF-R 
function may contribute to the movement of B cells during inflammation as BAFF-R is 
downregulated in the germinal center B cells (see Figure 4) (105). 
Expression patterns and the function of BAFF-R have been examined in RA and 
SLE patients. No difference in expression of BAFF-R was observed on B cells from SLE 
patients or from normal donors (71, 80). BAFF-R on CD19+ B cells was reduced 
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compared to healthy donors and negatively correlates with SLEDAI in patients classified 
as untreated new-onset SLE (76). However, elevated BAFF-R mRNA expression in total 
PBMCs positively correlated with SLEDAI scores and anti-dsDNA titers (77).  BAFF-R 
occupancy studies revealed that circulating B cells in SLE patients have consistently 
occupied BAFF-R which may lead to insensitivity of these cells to BAFF induced 
activation (71). BAFF-R expression is also increased in synovial tissue from patients with 
severe RA compared to mild RA and OA patients.  This BAFF-R expression was reduced 
on normal and RA B cells by treatment with NF-kb inhibitor indicating that BAFF 
engagement of BAFF-R results in the activation of the NF-kb pathway (81).  
 
TACI 
The transmembrane activator, calcium modulator, and cyclophilin ligand 
interactor (TACI) receptor and is a type III class of membrane protein.  TACI is the 
receptor for both BAFF and APRIL as well as heterotrimers of APRIL and BAFF (79). 
TACI is present of naïve mature B cells and on resting memory B cells (CD27+CD38-) 
within human spleen (71). The different functions of TACI are shown in Figure 4. TACI 
signaling has been shown to be responsible for B cell homeostasis and T-independent B 
cell activation.  TACI also stimulates class switch recombination in mature B cells (9). 
TACI expression on CD19+ B cells is increased in SLE patients with highest 
expression in SLE patients with lupus nephritis (76). Glomerular expression of TACI and 
BCMA mRNA is higher in lupus nephritis (101). Total PBMNC mRNA from SLE 
patients has higher levels of TACI receptor expression than healthy controls and 
positively correlates with disease activity (SLEDAI) and anti-dsDNA titers (77). RA and 
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SLE patients have elevated levels of hypomethylated DNA (106, 107) and increased 
expression of TLR9 (39). TLR9 stimulation by the hypomethylated DNA increases the 
expression of TACI and BCMA on human B cells and increases BAFF-R and TACI on 
murine B cells (84, 108).   
 
BCMA 
B cell maturation antigen (BCMA) is expressed on plasmablasts and plasma cells 
and is responsible for their survival (Figure 4). BCMA is a receptor for both BAFF and 
APRIL and has been implicated in RA or SLE. Plasmablasts within the normal human 
spleen express BCMA primarily (71). BCMA is expressed by fibroblast-like 
synoviocytes in RA synovial tissue and not found in OA tissues (96). Autoantibody 
producing B cells from SLE patients had higher levels of BCMA compared to BAFF-R 
compared to normal donors (109). 
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Figure 4: The Role of Secreted BAFF and APRIL Induced Signaling in B cells. The 
role of secreted APRIL and BAFF is dependent on which receptor these cytokines signal 
through. BAFF and/or APRIL have been shown to influence B cell survival, activation, 
chemotaxis, class switch recombination and plasma cell maintenance, all of which could 
have implications in RA and SLE disease activity. BAFF is the sole ligand for BAFF-R 
while both APRIL and BAFF bind and signal through TACI and BCMA. 
 23 
Therapeutics that Target APRIL and BAFF 
Disease activity measured by DAS28 in RA patients is reduced following biologic 
therapy however, inflammatory cells were still present within synovial biopsies from 
these patients (14) suggesting that therapies that target immune cells over cytokines may 
be more beneficial for RA patients.  T-independent B cell activation through the TNFSF 
members BAFF and APRIL and TLRs engagement is gaining attention as a potential 
contributor to autoimmune disease. Corticosteroids are often used as part of the treatment 
regimen for SLE and soluble BAFF but not APRIL levels decrease with treatment with 
high dose corticosteroids (100).  
Two biologics have been developed that antagonize APRIL and/or BAFF.  
Belimumab a monoclonal antibody that targets BAFF has recently been approved to treat 
SLE and is currently in clinical trials for the treatment of RA (110). The implication of 
APRIL in B-cell mediated autoimmune diseases led to the development of Atacicept, a 
humanized fusion protein of the Fc portion of IgG and TACI. Atacicept antagonizes both 
APRIL and BAFF and is currently in Phase III clinical trials for the treatment of SLE 
(111).  APRIL and BAFF have overlapping effects in B cell survival and maintenance, 
therefore this drug provides promise in targeting multiple autoreactive B cell subsets 
including plasma cells.  In animal models, Atacicept reduces IgM levels, reduces B cell 
numbers and plasma cells, reduces T-cell independent B cell response s in the spleen, and 
reduced disease activity but did not affect result in the reduction of memory B cells (112-
114). Atacicept has been shown to decrease the viability of activated human B cells and 
plasmablast and reduce levels of anti-dsDNA antibody production in SLE patients (20). 
The additional advantage of Atacicept is that it has the ability to neutralize heterotrimers 
of BAFF and APRIL detected in the serum of SLE and RA patients (79). This suggests 
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that Atacicept may be more effective treatment than Belimumab for SLE patients with 
elevated levels of BAFF-APRIL heterotrimers.  
 
Significance 
Together RA and SLE contribute to over 29 billion in healthcare costs, therefore 
due to the high financial burden and physical toll of these diseases on the population, 
there is a critical need to effectively and efficiently diagnose and treat RA and SLE 
patients (115). The aim of our studies was to identify biomarkers and drug targets to 
improve the identification and treatment of RA and SLE patients. As discussed above, 
APRIL, BAFF and TSLP have been implicated in the pathogenesis of RA and SLE.  
Therefore we sought to determine the role of these cytokines in our RA and SLE patient 
cohort. Our central hypothesis is that expression patterns of surface as well as soluble 
forms of APRIL and BAFF contribute to B cell mediated pathogenesis in RA and SLE 
and that these expression patterns can be used to determine patient disease activity, and 
predict response to the biologics that specifically target these cytokines.  In addition, we 
hypothesize that TSLP augments APRIL and BAFF production by DCs contributing to a 
pro-inflammatory environment locally in the joints of RA patients and systemically in 
SLE patients. These studies provide insight into the role of APRIL and TSLP in 
autoimmune cell activity and provide a rationale to guide treatment strategies based upon 
the expression of APRIL, BAFF, and TSLP. This work is significant because it has the 
potential to provide clinicians with easily accessible biomarkers to identify the best 
treatment plan to target these cytokines and their function in pathways involved in RA 
and SLE pathogenesis.  
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Abstract 
Objectives: To assess surface APRIL (CD256) expression by circulating myeloid cells in 
rheumatoid arthritis (RA) and to determine its relationship to patient disease activity.  
Methods: Peripheral blood mononuclear cells (PBMNCs) and plasma were obtained 
from RA patients and normal donors. PBMNCs were stained for flow cytometry to detect 
surface APRIL and blood cell markers to identify circulating myeloid cell subsets. Based 
on CD14 and CD16 phenotypes, monocyte subsets described as classical (CD14+CD16–
), intermediate (CD14+CD16+), and non-classical (CD14loCD16+) were identified. 
Levels of surface APRIL expression were measured by flow cytometry and median 
fluorescence intensity (MFI) was used for comparisons. Levels of soluble APRIL in the 
plasma were determined by ELISA. Disease activity was measured by Disease Activity 
Score out of 28 joints (DAS28). 
Results: In RA patients, total myeloid cells showed expression of surface APRIL which 
correlated with disease activity and with plasma APRIL levels observed in these patients. 
In normal donors, classical monocytes comprised >80% of circulating monocytes. 
However, in RA patients, the intermediate and non-classical subsets were elevated and 
made up the majority of circulating monocytes. In contrast to normal donors, where high 
levels of surface APRIL were only observed on non-classical monocytes, RA patients 
showed high levels of surface APRIL expression by all circulating monocyte subsets.  
Conclusions: Surface APRIL is elevated on circulating myeloid cells in RA patients 
where it is highly correlated with disease activity. RA patients also showed skewing of 
monocytes toward subsets associated with secretion of TNF-α and/or IL-1β. 
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Abbreviations 
 
RA - Rheumatoid Arthritis 
APRIL - A Proliferation Inducing Ligand 
TNFSF - Tumor Necrosis Factor Super Family 
FLS - Fibroblast-Like Synoviocytes 
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Interactor 
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MFI – Median Fluorescence Activity 
FSC - Forward Scatter 
SSC - Side Scatter 
BAFF - B cell Activating Factor 
VERA – Very Early Rheumatoid Arthritis 
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Introduction 
Rheumatoid arthritis (RA) is a systemic B cell-mediated autoimmune disease 
dominated by autoantibodies that recognize intra- and extracellular antigens (1,2). These 
autoantibodies result in chronic systemic immune responses that target the synovium, 
cartilage, and bone resulting in joint damage (3). During inflammatory synovitis, immune 
cells infiltrate the joint and produce cytokines (4). Stimulation by cytokines induces B 
cells at different stages of development to proliferate and differentiate into antibody-
producing plasma cells, thus continuing the cycle of chronic inflammation in RA (5-7). 
Studies of B-cell mediated autoimmune disease implicate the cytokine, APRIL (A 
PRoliferation-Inducing Ligand), as a potential disease mediator. APRIL has been shown 
to support B cell development and survival in mice and humans (5). APRIL is a member 
of the tumor necrosis factor super family (TNFSF) and is secreted by monocytes (8), 
dendritic cells (9), macrophages (10), neutrophils, myelocytes (8), astrocytes (11), 
adipocytes (12), and activated T and B cells (13). Elevated levels of APRIL have been 
measured in the serum and synovial fluid of RA patients (14,15). In addition, fibroblast-
like synoviocytes (FLS) have been shown to secrete APRIL in RA, but not osteoarthritis 
(16).  Novel surface forms of APRIL have recently been reported in human cell lines 
derived from lymphoid (17) and myeloid malignancies (18). In addition, surface APRIL 
has been observed by microscopy on synovial macrophages from RA patients (18). 
The effects of APRIL are dependent on the receptor that it binds. APRIL has two 
receptors: 1) TACI (the Transmembrane Activator, Calcium modulator) and cyclophilin 
ligand Interactor receptor and 2) BCMA (the B-Cell Maturation Antigen receptor). TACI 
is expressed on B-cells (19) while BCMA expression has been reported on plasma cells 
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and on FLS from RA patients (16). Binding of APRIL to the TACI or BCMA receptor 
leads to increased B cell or plasma cell survival, respectively (20).  
Monocytes exist as a heterogeneous population in the blood of healthy individuals 
and three subsets have been identified based on the expression of surface CD14 and 
CD16.  Classical monocytes (CD14+CD16–) comprise the majority (~90%) of 
circulating monocytes. Intermediate monocytes (CD14+ CD16+) have been described as 
pro-inflammatory monocytes (21,22). Non-classical monocytes (CD14loCD16+) are also 
called patrolling monocytes and make up the minority subset in the circulating monocyte 
pool (23). Classical monocytes are excellent phagocytes and produce IL-6 and IL-8 in 
response to bacterial pathogens. Intermediate monocytes produce the pro-inflammatory 
cytokines TNF-α and IL-1β (24). Non-classical monocytes exhibit vascular patrolling 
activity, poor phagocytic ability, and secrete pro-inflammatory cytokines TNF-α and IL-
1 in response to TLR7 and TLR8 stimulation. These non-classical/patrolling monocytes 
are increased in active RA and are present in the glomerular vessels of lupus patients with 
lupus nephritis (25-29).  
Increases in serum levels of soluble APRIL, and in specific myeloid cell 
populations, have been associated with RA. A novel surface form of APRIL has been 
identified and recent studies link its expression to myeloid cells and RA (18). However, 
expression of surface APRIL by monocyte subsets in normal individuals and its 
relationship to RA are unknown. In this study, we sought to compare surface APRIL 
expression on circulating myeloid cells in both normal and autoimmune patients, and to 
determine whether expression of surface APRIL is related to plasma levels of soluble 
APRIL and disease activity in RA patients. Here we show that surface APRIL is elevated 
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on circulating myeloid cells and correlates with disease activity in RA. In normal donors 
surface APRIL was only observed on non-classical monocytes which make up ~5% of 
circulating monocytes. In contrast, all monocyte subsets showed high levels of surface 
APRIL in RA patients. While intermediate and non-classical subsets made up <20% of 
circulating monocytes in normal donors, they comprised the majority of circulating 
monocytes in RA patients. 
 
Materials And Methods 
Subjects 
 Subjects were enrolled in this study and gave informed consent under a protocol 
approved by the Loma Linda University (LLU) Institutional Review Board.  All RA 
patients were from Loma Linda University Division of Rheumatology Clinic, Loma 
Linda California or Beaver Medical Group Rheumatology Clinic, Redlands, CA USA. 
All patients had a clinical diagnosis of RA and met the 1987 American College of 
Rheumatology criteria (30). Disease Activity Score out of 28 joints (DAS28) was used as 
a measure of RA disease activity (see Table 1). The total patient population consisted of 
26 patients (23 females and 3 males) with a mean age of 55.2 ± 15.6 years. Normal 
peripheral blood (PB) from anonymous adult donors was obtained from Leuko-pak 
leukocyte filters (Fenwal Laboratories, Lake Zurich, IL, USA), and donated by the Blood 
Processing and Quality Control Lifestream in San Bernardino, CA.  Normal plasma was 
purchased from Tennessee Blood Services, Memphis, TN, USA. 
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Table 1: Clinical Characteristics of the RA Patient Population 
Patient Sex/Age Disease 
Duration 
(years) 
RF 
(+/-) 
DAS28 Treatment 
 
Assay 
1 M/58 15 pos 0.77 NONE ELISA, FC 
2 F/47 10 pos 1.4 MTX  FC 
3 F/57 15 pos 1.53 MTX, Etanercept FC 
4 F/66 24 pos 1.56 LEF ELISA, FC 
5 F/26 12 neg 2.09 Adalimumab FC 
6 F/38 9 neg 2.3 MTX, Rituximab FC 
7 F/61 26 neg 2.3 MTX, Etanercept FC 
8 F/42 11 pos 2.35 Etanercept ELISA, FC 
9 F/64 5 pos 2.35 MTX, HCQ ELISA, FC 
10 F/42 4 neg 2.66 Adalimumab FC 
11 F/62 1 pos 2.72 MTX, PDN  ELISA, FC 
12 F/64 6 neg 2.8 MTX, HCQ FC 
13 F/43 27 pos 2.82 MTX, Adalimumab FC 
14 F/56 28 pos 3.34 MTX, PRED ELISA, FC 
15 F/75 15 NR 3.57 MTX, Infliximab FC 
16 F/75 15 NR 3.57 MTX, Infliximab FC 
17 M/46 1 pos 3.7 LEF ELISA, FC 
18 F/47 25 neg 3.8 Naproxen FC 
19 F/21 3 pos 4.35 NONE ELISA, FC 
20 F/33 1 neg 4.58 HCQ FC 
21 F/70 4 neg 4.73 MTX, HCQ ELISA, FC 
22 F/75 5 pos 4.75 MTX  ELISA, FC 
23 F/61 6 pos 4.99 MTX, Adalimumab ELISA, FC 
24 F/56 29 pos 5.13 MTX, PRED, LEF ELISA, FC 
25 M/60 4 pos 6.95 NONE FC 
26 F/68 10 NR NR MTX ELISA, FC 
 
NR: not reported, MTX: methotrexate, PRED: prednisone, LEF: leflunomide, HCQ: 
hydroxychloroquine, ELISA: Enzyme-linked immunosorbent assay, FC: Flow cytometry 
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Sample Preparation 
Blood samples were collected in tubes containing acid citrate dextrose (ACD) 
from Becton, Dickinson and Company (Franklin Lakes, NJ, USA).  Whole blood samples 
were centrifuged at 1500rpm for 15 minutes to remove plasma.  Peripheral blood 
mononuclear cells (PBMNCs) were obtained by red blood cell (RBC) lysis using an 
ammonium chloride based RBC lysis buffer in both RA patient and normal PB samples.  
 
Soluble Cytokine Quantification 
Plasma levels of APRIL were determined by a sandwich ELISA (Human APRIL 
Platinum ELISA, Bender MedSystems GmbH, Vienna, Austria). ELISAs were performed 
according to manufacture’s instructions on freshly thawed plasma. The ELISA plates 
were read at 450nm absorbance using the uQuant 96 well plate reader (Bio-Tek 
Instruments, Inc., Winooski, VT, USA). A standard curve was run in triplicate for each 
plate and samples were run in triplicate. APRIL plasma levels were calculated using a 
linear model in Bio-Tek software KCJunior V1.6 (Winooski, VT, USA).  
 
Flow Cytometry 
PBMNCs from RA and normal donors were stained with mAbs in PBS for 30 
minutes in the dark at 4ºC. Cells were then washed with PBS and stained with Fixable 
Viability Dye eFluor® 450 (eBioscience) to distinguish between living and dead cells 
and incubated for 30 minutes at 4ºC in the dark. Cells were subsequently washed and 
fixed with a 1% paraformaldehyde solution before analysis using the MACSQuant® 
Analyzer (Miltenyi Biotec). The following isotype control antibodies were used: mouse 
IgG1 FITC, mouse IgG1 PE–Cy7 (eBioscience, San Diego, CA, USA); mouse IgG1 
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APC-Cy7, rat IgG2b PerCP-Cy5.5 (Biolegend, San Diego, CA, USA); mouse IgG1 PE, 
mouse IgG1 APC (Miltenyl Biotech Inc., Auburn, CA, USA). The anti-human antibodies 
used were: CD256 PE (clone T3-6), CD66b PerCP-Cy5.5 (clone G10F5), CD1a APC 
(clone HI149), CD16 APC-Cy7 (clone 3G8) (Biolegend, San Diego, CA, USA); CD14 
PE-CY7 (clone 61D3) (eBioscience, San Diego, CA, USA). Compensation beads (anti-
mouse Ig k compensation beads, BD Biosciences, San Jose, CA, USA) and cells stained 
with Fixable Viability Dye eFluor® 450 were used for machine compensation settings.  
Flow cytometry alignment particles were used as an instrument settings control for each 
experiment (Sphero™ Ultra Rainbow Fluorescent Particles, Lake Forest, IL, USA). Flow 
cytometry data analysis was performed using Flowjo data analysis software (TreeStar, 
Ashland, OR).  Relative surface APRIL expression for RA patients was obtained by 
normalizing the APRIL MFI of each patient sample to the mean APRIL MFI obtained for 
normal samples (n>11) that were stained with the same antibody combinations and 
collected with the same instrument settings as the RA patient sample.  
 
Statistical Analysis 
Statistical differences were determined using non-parametric Mann-Whitney two 
–tailed tests using GraphPad PRISM software (GraphPad, San Diego, CA, USA). 
Correlation analysis was performed using Spearman’s one-tailed test.  Differences were 
considered to be statistically significant for p<0.05. Grubb’s Test was used to exclude 
significant outliers. The mean and 95% confidence interval is shown in each graph. 
Asterisks within the figures indicate the following p values: *p<0.05, **p<0.01, 
***p<0.001, and ****p<0.0001. 
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Results 
Surface APRIL Expression is Elevated on  
Circulating Myeloid Cells in RA Patients 
Multiple blood cells have been shown to produce and secrete APRIL(8-13). 
Surface APRIL expression has been reported on malignant myeloid cell lines (17) and on 
macrophages in synovial tissues in RA patients (16,31). However, expression of APRIL 
by circulating myeloid cells has not been reported. We used multi-color flow cytometry 
to determine whether surface APRIL is expressed on peripheral blood myeloid cells in 
RA patients and normal donors. For flow cytometry analysis, intact peripheral blood 
mononuclear cells (PBMNCs) were gated based on forward (FSC) and side (SSC) light 
scatter (Figure 5A left panels). These cells were further gated to identify living cells 
(cells that were negative for viability dye, Figure 5A middle panels). From intact living 
cells, myeloid cells were identified based on size (indicated by FSC) and granularity 
(indicated by SSC) (gate shown in Figure 5A right panel).  
Surface APRIL was clearly detectable on gated myeloid cells from all RA patients 
as compared to isotype controls (Figure 5B). In contrast, the majority of normal donor 
samples showed surface APRIL staining that was similar or slightly higher than isotype 
controls (Figure 5B). A graph comparing the median fluorescence intensity (MFI) of 
surface APRIL staining on gated myeloid cells from 16 normal donors and 15 RA 
patients is shown in Figure 5C. These data show that surface APRIL is elevated on 
myeloid cells in RA patients as compared to normal controls (p=<0.0001).   
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Figure 5. Surface APRIL expression is elevated in RA. A. PBMNCs from normal 
donors and RA patients were stained for flow cytometry to detect surface APRIL and 
with viability dye. Forward (FSC) and side (SSC) light scatter and intact cell gate are 
shown (left panels). From these, living cells were gated (middle panels). Total myeloid 
cells were gated from living intact cells based on FSC and SSC (right panels). B. 
Representative histograms show surface APRIL and isotype staining in gated myeloid 
cells. C. Graphed is the median fluorescence intensity (MFI) of surface APRIL staining 
on gated myeloid cells from 16 normal donors and 15 RA patients. 
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Surface APRIL Expression Correlates With Plasma Levels  
of Soluble APRIL in RA Patients 
Elevated levels of soluble APRIL have been reported in the serum of RA patients 
(16,32,33); therefore, we wanted to determine whether there was a correlation between 
surface APRIL expression and levels of soluble APRIL circulating in the plasma of RA 
patients. Plasma APRIL levels were measured in 15 RA patients and 11 normal donors 
by ELISA. Plasma levels of APRIL were increased in RA patients as compared to normal 
donors (19.92 ± 25.02 versus 2.12 ± 4.44 ng/mL; Figure 6A). These data confirm 
previous reports that soluble APRIL is elevated in RA (16,32,33).  
Next we evaluated the relationship between surface APRIL expression and 
plasma levels of soluble APRIL in RA patients. Plasma APRIL levels and surface APRIL 
expression on myeloid cells (gated as shown in Figure 5A) were determined in RA 
patients. Patient characteristics are shown in Table 1. Relative surface APRIL expression 
was calculated by normalizing the APRIL MFI for each patient sample to the mean 
APRIL MFI obtained from normal donor samples. Spearman’s rho analysis shows a 
positive correlation between relative surface APRIL expression by myeloid cells and 
plasma APRIL levels in RA patients (r=0.514 p=0.038; Figure 6B).   
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Figure 6: Level of surface APRIL on myeloid cells correlates with soluble APRIL in 
plasma of RA Patients. A. Soluble APRIL in plasma from normal donors (n=11) and 
RA patients (n=15) was determined by ELISA. B. Surface APRIL expression by myeloid 
cells from RA patients was determined by flow cytometry. MFI of surface APRIL 
staining in RA patients was normalized to that of normal donors to determine the relative 
APRIL MFI. The Spearman’s rho test indicates that relative surface APRIL expression 
on myeloid cells is highly correlated with plasma APRIL levels in n=13 RA patients.  
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Surface APRIL Expression Correlates 
With Increased Disease Activity in RA 
Soluble APRIL has been shown to correlate with disease activity in lupus 
nephritis, systemic lupus erythematous, and juvenile idiopathic arthritis (15,34,35). 
Increased soluble APRIL levels have been reported in RA patients with active disease 
(14). Here we evaluated the relationship between surface APRIL expression on myeloid 
cells and disease activity in RA. The MFI for expression of surface APRIL was 
calculated as described above. Disease Activity Score in 28 joints (DAS28) found in 
Table 1, was used to determine the disease activity in our RA patient cohort. In Figure 7, 
Spearman’s rho analysis shows that relative surface APRIL expression by myeloid cells 
in RA patients positively correlates with DAS28 (r=0.499 p=0.006). Spearman’s rho 
analysis of soluble APRIL did not show a correlation with disease activity in the RA 
patients we studied, although their levels of soluble APRIL were elevated as compared to 
normal donors. These data show that surface APRIL expression by myeloid cells in RA 
patients correlates with disease activity as indicated by DAS28 score.  
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Figure 7: Level of surface APRIL on myeloid cells correlates with disease activity in 
RA Patients. Surface APRIL expression by myeloid cells from RA patients was 
determined by flow cytometry. MFI of surface APRIL staining in RA patients was 
normalized to that of normal donors to determine the relative APRIL MFI. The 
Spearman’s rho test indicates that relative surface APRIL expression on myeloid cells is 
highly correlated with disease activity as determined by DAS28 in n=25 RA patients. 
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Frequency Of Intermediate and Non-Classical Monocytes are 
Increased in the Circulating Monocyte Pool of RA Patients 
Given the relationship that we observed between surface APRIL on circulating 
myeloid cells and disease activity in RA patients, we sought to identify the subsets of 
myeloid cells responsible for increased surface APRIL expression. Circulating myeloid 
cells include monocytes as well as very short-lived neutrophils. Previous reports have 
shown that monocytes are associated with inflammation and that a subset of these 
monocytes, described as non-classical (CD14loCD16+), is increased in patients with 
active RA (24,26). Here we used flow cytometry to compare the frequency of classical, 
intermediate and non-classical monocyte subsets among circulating myeloid cells in 
normal donors and our RA patient cohort. PBMNC samples were stained with antibodies 
to detect CD66b, CD14 and CD16. Cells within myeloid light scatter (Figure 8A, left 
panels) were gated from intact, living PBMNCs as shown in Figure 5A. Monocytes were 
distinguished from short-lived granulocytes (<1% of living cells in all samples) based on 
granularity (indicated by side scatter, SSC) and the absence of the granulocyte marker 
CD66b (gated as shown in Figure 8A, middle panels). The co-expression pattern of CD14 
and CD16 was used to phenotypically identify myeloid cells that have been described as 
classic (CD14+CD16–) intermediate (CD14+CD16+) and non-classical (CD14loCD16+) 
monocytes (23) (Figure 8A, right panels).   
Flow cytometry plots of monocytes in RA samples show a clear increase in CD16 
expression that results in a shift from predominantly classical monocytes (CD14+CD16–) 
to inflammatory intermediate (CD14+CD16+) and non-classical (CD14loCD16+) 
monocytes. This shift (Figure 8A, right panels) was observed in 12 out of 15 RA patients 
(The CD14 vs CD16 plots for monocyte subsets in each normal and RA sample are 
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shown in Figure 10 and Figure 11). A comparison of the frequency of each monocyte 
subset within the total circulating monocyte pool revealed that the proportion of 
intermediate and non-classical monocytes were increased (~8 and ~4 fold, respectively), 
while the proportion of classical monocytes was reduced in RA patients as compared to 
normal controls (Figure 8B). These data show that the pool of circulating monocytes in 
RA patients is skewed toward pro-inflammatory, intermediate and non-classical subsets. 
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Figure 8. The circulating monocyte pool is skewed toward intermediate and non-
classical monocytes in RA. A. PBMNCs from RA patients and normal donors were 
stained for flow cytometry to detect CD66b, CD14 and CD16. Myeloid cells were gated 
(left panels) as in Figure 5. Expression of CD66b versus SSC was plotted and monocytes 
were gated based on low side scatter and absence of CD66b (middle panels.) Co-staining 
with CD14 and CD16 was used to identify 3 subsets of monocytes (right panels). B.  
Graphed is the percentage of each subset within the total monocyte pool in normal donors 
(n=16) and RA patients (n=15). 
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Surface APRIL Expression is Elevated on PB Monocyte Subsets 
Surface APRIL expression has been identified on monocytic leukemia (THP-1) 
and monocytic lymphoma (U937) cell lines and on primary macrophages from RA 
patients (16,31). Our data in Figure 5C show surface APRIL expression on some myeloid 
cells in normal samples, and that this expression is elevated in RA patients. Next we 
sought to determine normal surface APRIL expression in monocyte subsets and how this 
compares to RA patients. We evaluated expression of surface APRIL in monocyte 
subsets gated as described in Figure 5A. Our data show that in RA patients, levels of 
surface APRIL are elevated in classical and intermediate monocytic subsets as compared 
to normal donors (Figure 9A-B). APRIL levels were on average increased 3-fold in 
classic monocytes and increased 6-fold in intermediate monocytes as compared to normal 
donors. However, there was no significant difference in APRIL expression when non-
classical monocytes in RA patients and normal donors were compared (Figure 9C). These 
data show that in RA patients surface APRIL is upregulated in classical and intermediate 
monocytes as compared to normal donors. 
To gain insights into the potential role of surface APRIL in normal monocytes we 
compared expression across the classical, intermediate and non-classical subsets (Figure 
9D). In normal donors, we found that surface APRIL is undetectable on classical 
monocytes, expressed at very low levels on intermediate monocytes, and at high levels on 
non-classical monocytes (Figure 9D). In contrast, RA patients showed similarly high 
levels of surface APRIL across all monocyte subsets. (Figure 9E). Taken together these 
data suggest that in RA all monocyte subsets express high levels of surface APRIL 
normally found only on non-classical monocytes. 
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Figure 9. Surface APRIL is elevated on classical and intermediate monocytes in RA 
patients. PBMNCs from RA patients and normal donors were stained for flow cytometry 
and monocyte subsets were gated as in Figure 8. The MFI of APRIL staining on 
monocytes in the (A) classical (B) intermediate, and (C) non-classical subsets in RA 
patients (n=15) and normal donors (n=16) is plotted. Graphed is a comparison of surface 
APRIL among monocyte subsets in (D) normal donors (n=16) and (E) RA patients 
(n=15). 
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Discussion 
Surface forms of APRIL have been identified on cell lines from lymphoid (17) 
and myeloid malignancies (18) as well as macrophages in the synovial tissue of RA 
patients (31). Therefore, we sought to determine whether circulating myeloid cells in RA 
patients express surface APRIL. We show that circulating myeloid cells in RA patients 
express surface APRIL (Figure 5B and 5C) and this surface APRIL expression positively 
correlates with disease activity in our RA patient cohort (Figure 7). Thus, our studies are 
the first to show that surface APRIL is expressed on circulating myeloid cells in RA 
patients and that levels of surface APRIL are highly correlated with disease activity. 
Next we sought to determine which myeloid cell subset(s) are responsible for 
elevated surface APRIL in RA. Previous reports have shown that the frequency of non-
classical monocytes is higher in patients with active RA (26-28). We show that both non-
classical and intermediate monocyte subsets are increased in RA patients (Figure 8B). 
Although these subsets make up less than 20% of the circulating monocyte population in 
normal donors, in RA patients they represent the majority of circulating monocytes 
(Figure 8B). Intermediate monocytes are believed to represent a subset of monocytes that 
are able to rapidly mature and differentiate into tissue macrophages due to their 
expression of CD16 (36). They also migrate in response to the chemokine CX3CL1 (37), 
which is elevated in RA patients (38). Thus, the pool of monocytes in RA patients is 
skewed toward intermediate and non-classical monocytes, populations of monocytes 
known to produce the inflammatory cytokines TNF-α and/or IL-1β (25), cytokines 
important in the pathogenesis of RA. 
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Our evaluation of monocyte subsets from normal donors showed that staining for 
surface APRIL is not above background in the classical monocytes. Low levels of surface 
APRIL were observed on intermediate monocytes, while high levels of surface APRIL 
were only detected on non-classical monocytes in normal donors (Figure 9D). In contrast, 
surface APRIL is expressed at high levels on all monocyte subsets in RA patients (Figure 
9E). Overall, our data suggest that in RA patients a large fraction of monocytes take on 
features characteristic of the pro-inflammatory monocyte subsets (Supplemental Figure 
10 and Figure 11). Specifically, monocytes in RA patients show elevated levels of CD16 
(Figure 8A), a feature characteristic of intermediate and non-classical monocytes, as well 
as high levels of surface APRIL, which in healthy donors was only found on non-
classical monocytes (Figure 9D-E.)  
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Figure 10. Monocyte subsets in RA patients. Flow cytometry plots showing CD14 
versus CD16 co-staining on gated monocytes in PBMNCs from RA patients (n=15). The 
frequency of gated monocyte for each subset is provided. 
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Figure 11. Monocyte subsets in Normal Donors. Flow cytometry plots showing CD14 
versus CD16 co-staining on gated monocytes in PBMNCs from normal donors (n=16). 
The frequency of gated monocyte for each subset is provided. 
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Surface APRIL has the potential to contribute to RA by acting either as a ligand 
or as a receptor during interactions with TACI and BCMA. TACI and BCMA are 
receptors for soluble APRIL. TACI is expressed on normal and malignant B cells, while 
BCMA is expressed on plasmablasts, plasma cells and on FLS cells in RA joints 
(16,17,39-43). Cell-to-cell contact between monocytes that express surface APRIL and B 
lineage cells that express TACI or BCMA have the potential to contribute to RA. It is 
currently unclear whether surface APRIL gives the same pro-survival signals that soluble 
APRIL produces in B lineage cells. This will be an important area for future studies. 
Surface APRIL has also been shown to act as a signaling receptor when 
stimulated by interaction with TACI or BCMA. Monocytic leukemia cells expressing 
surface APRIL produced both IL-8 and MMP-9 when co-cultured with B cells that 
expressed either TACI or BCMA (18). Since FLS and plasma cells in the RA joint 
express BCMA, it is possible that cell-to-cell contact results in BCMA-induced surface 
APRIL signals in myeloid cells and the secretion of pro-inflammatory cytokines that 
ultimately leads to joint destruction. 
Alternative APRIL splice forms give rise to surface APRIL (44). APRIL is 
classically processed intracellularly within the Golgi apparatus and is then secreted from 
the cell45. An intergenic splice form exists that is generated from the combination of 
exons 1-6 of TWEAK and exons 2-6 of APRIL producing TWE-PRIL (46). The TWE-
PRIL splice form has the transmembrane domain of TWEAK and the trimeric form of 
APRIL as an uncleaveable membrane bound protein (46). TWE-PRIL and other 
alternative splice forms of APRIL may lead to the surface expression of APRIL (44). 
Here we show that surface APRIL is elevated on circulating myeloid cells in RA patients. 
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The function of surface APRIL in the pathology of rheumatic diseases has not been 
elucidated and will be a focus for future studies.  
The implication of APRIL in B-cell mediated autoimmune diseases led to the 
recent development of Atacicept and other drugs currently under development (47). 
Atacicept antagonizes APRIL as well as another cytokine, B-cell activating factor 
(BAFF) and is currently in Phase III clinical trials for the treatment of SLE (48). APRIL 
and BAFF have overlapping effects in B cell survival and maintenance, therefore, this 
drug provides promise in targeting multiple autoreactive B cell subsets including plasma 
cells by preventing APRIL and/or BAFF from activating TACI, BAFF receptor and 
BCMA. We speculate that Atacicept could also lead to the removal of monocyte 
populations that aberrantly express surface APRIL.  
In two Phase II clinical trials for RA (August I and II), Atacicept reduced RF 
antibody levels, mature B cells, and plasma cells in patients with inadequate response to 
either MTX or anti-TNF therapy (49,50). However, these trials failed to meet the primary 
ACR20-CRP response endpoint (49,50), possibly due to patient selection criteria. Future 
trials with Atacicept may prove effective in treating patient cohorts with elevated 
expression of APRIL/BAFF. Data in Figure 7 indicate that ~50% of our RA cohort show 
moderately elevated surface APRIL, and ~30% have surface APRIL that is more than 3 
fold higher than that of normal donors, suggesting that Atacicept may only be effective in 
a subset of patients.  
APRIL and BAFF have been shown to be particularly elevated in very early RA 
(VERA) suggesting that Atacicept (14,51) may prove beneficial in newly diagnosed RA 
patients. While all of our patients had established RA, the positive correlation we saw 
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between plasma APRIL and surface APRIL on myeloid cells suggests that the surface 
APRIL levels may be even higher in VERA. Our findings suggest that surface APRIL 
could provide an easily detectable biomarker and be a useful selection criterion for the 
administration of Atacicept. Surface APRIL expression, together with monocyte subset 
skewing, might provide a prognostic indicator of RA patient response to Atacicept or 
other drugs that target APRIL (47).  
In conclusion, APRIL is expressed on circulating myeloid cells in RA patients 
and positively correlates with DAS28 measurement of disease activity. In RA patients, 
circulating monocytes are skewed toward subsets associated with inflammation and all 
monocyte subsets show the high levels of surface APRIL normally found only on non-
classical monocytes. Further studies are needed to determine the mechanisms responsible 
for surface APRIL expression and its role in RA pathogenesis. 
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CHAPTER THREE 
CHARACTERIZATION OF THE SURFACE EXPRESSION OF APRIL AND BAFF 
AND THEIR RECEPTORS ON B CELLS SUBSETS FROM RHEUMATOID 
ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOUS PATIENTS 
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Abstract 
Background: Autoimmune disease affects more than 23 million Americans. Rheumatoid 
Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are chronic, systemic B cell 
mediated autoimmune diseases. During normal B cell development, autoreactive B cells 
are eliminated by negative selection processes that include receptor editing, anergy, or 
apoptosis. The increased numbers of autoreactive B cells and autoantibodies found in RA 
and SLE patients suggests that these patients have defects in negative selection that 
occurs during the immature stages of B cell development. The tumor necrosis factor 
(TNF) family members APRIL and BAFF have been shown to promote the survival of 
immature and naïve B cells in mouse models of autoimmune disease. Elevated levels of 
APRIL and BAFF may contribute to the breakdown of negative selection mechanisms. 
Serum levels of APRIL and BAFF are elevated in patients with RA and SLE and surface 
forms of these proteins have been detected on peripheral blood cells from SLE patients 
and on malignant B lineage cells.  Using flow cytometry, we found surface forms of 
APRIL and BAFF on peripheral blood B cells from RA and SLE patients. The aim of this 
study was to compare surface expression of APRIL and BAFF and their receptors on B 
cells from SLE and RA patients to normal B cells and to elucidate their roles in B cell 
mediated autoimmunity. 
Methods: Venous peripheral blood (PB) samples were collected from normal, RA, and 
SLE patients through an IRB-approved protocol. RA and SLE diagnosis was confirmed 
using American College of Rheumatology (ACR) criteria. Peripheral blood mononuclear 
cells (PBMNCs) were separated from whole blood by red blood cell lysis. Human adult 
peripheral blood samples were stained for seven-color flow cytometry to assess co-
expression of CD24, CD21, IgD, IgM, CD38, CD27, CD256 (APRIL), CD257 (BAFF), 
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CD267 (TACI), and BR3 (BAFF-R). Stained cells were analyzed using a MACSQuant 
Analyzer (Miltenyi) and FlowJo analysis software (Tree Star). Mean fluorescence 
intensities (MFI) for surface APRIL and other markers on B cells from RA and SLE 
patient samples were compared to normal controls by one-tailed, unpaired t-test, p<0.05. 
Results: Peripheral blood B cells obtained from normal (n=11), SLE (n=10), and RA 
(n=16) were characterized by flow cytometry. The MFI of APRIL, BAFF, BAFF-R and 
TACI on total CD19+ B cells of RA and SLE patients were compared to normal PB. 
Surface APRIL expression was significantly higher on B cells from RA and SLE  patients 
as compared to normal donors. The greatest surface ARPIL staining was identified on 
transitional B cells. BAFF was elevated on RA and SLE CD19+ B cells with greatest 
expression found on the CD27+ memory B cell subset in RA patients. BAFF-R was 
elevated on all B cell subsets with greatest expression on transitional B cells in RA 
patients. TACI receptor, which binds both APRIL and BAFF was also increased on 
IgM+, CD27+ memory B cells, transitional and mature B cell subsets in RA and SLE 
patients.   
Conclusions:  Surface APRIL is expressed on total CD19+ and developmental B cell 
subsets in RA and SLE patients and positively correlates with disease activity in RA 
patients. Surface BAFF is elevated on CD19+ and developmental B cell subsets in RA 
and SLE patients with the highest expression found on CD27+ memory B cells in RA 
patients. BAFF-R is elevated on B cell subsets in RA patients and negatively correlates 
with disease activity in SLE patients. In both RA and SLE, TACI receptor is elevated on 
B cell subsets with the highest expression identified on transitional B cells. The elevated 
expression of surface APRIL and BAFF on B cell subsets in established RA and SLE 
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patients suggest that these cytokines may serve as potential biomarkers for the 
identification of RA and SLE.  Further testing is needed to determine how patients with 
elevated levels of surface APRIL and BAFF respond to targeted therapy by Belimumab 
and Atacicept. 
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Abbreviations 
RA - Rheumatoid Arthritis 
SLE - Systemic Lupus Erythematosus  
BAFF - B cell Activating Factor  
APRIL - A Proliferation Inducing Ligand 
TACI - Transmembrane Activator, Calcium Modulator, and Cyclophilin Ligand 
Interactor 
BCMA - B-cell Maturation Antigen 
BAFF-R - B cell Activating Factor Receptor 
TNF-α - Tumor Necrosis Factor Alpha 
ILX- Interleukin 
TNFSF - Tumor Necrosis Factor Super Family 
DAS28 - Disease Activity Score out of 28 Joints 
SLEDAI – SLE Disease Activity Index 
PB - Peripheral Blood 
PBMNCs - Peripheral Blood Mono Nuclear Cells 
CD – Cluster of Differentiation 
MFI – Median Fluorescence Activity 
FLS - Fibroblast-Like Synoviocytes 
ELISA – Enzyme Linked Immune Sorbent Assay 
SSC - Side Scatter 
FSC - Forward Scatter 
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Introduction 
Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are B cell-
mediated autoimmune diseases dominated by autoantibodies that recognize cellular 
antigens (1, 2). These autoantibodies cause chronic systemic immune responses that 
result in debilitating pain and multi-organ damage (3). As B cells develop and 
differentiate into antibody-producing plasma cells, where they can be stimulated to 
proliferate and/or survive at different stages in the process by secreted BAFF (B cell 
activating factor) and APRIL (a proliferation inducing ligand) cytokines (4-6). 
The effects of APRIL and BAFF are dependent on the receptor that it binds. 
APRIL has two receptors: 1) the transmembrane activator, calcium modulator, and 
cyclophilin ligand interactor (TACI) receptor and 2) the B-cell maturation antigen 
(BCMA) receptor. BAFF shares TACI and BCMA with APRIL and has an exclusive 
receptor BAFF-R (B cell activating factor receptor). BAFF-R and TACI are expressed on 
B-cells (7) while BCMA expression has been reported on plasma cells and on fibroblast-
like synoviocytes (FLS) from RA patients (8). APRIL and BAFF have been shown to 
influence B cell survival, activation, chemotaxis, and class switch recombination, all of 
which could have implications in RA and SLE disease activity (9-14).  
Consistent with the ability of these cytokines to support B cell development, 
elevated levels of BAFF and APRIL have been measured in the serum and synovial fluid 
in RA and SLE (15, 16). APRIL and BAFF are upregulated in response to B cell 
activation due to dsDNA autoantibody exposure, which is present in both RA and SLE 
patients (12, 17). These cytokines have been further implicated in B cell-mediated 
pathologies by the recent identification of surface forms of BAFF and APRIL on 
leukemic B cells and monocytes, and the report of surface BAFF on B cells from patients 
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with active SLE (9, 18-22). In synovial fibroblasts, treatment with APRIL leads to the 
increase of APRIL and the inflammatory cytokines TNF-α, IL-6 and IL-1β (8). 
Functional analysis of surface APRIL in malignant monocytes showed that stimulation of 
surface APRIL with soluble TACI induced the production of IL-8 and MMP-9, and 
suppression of phagocytosis, thereby initiating a pro-inflammatory state (21). 
Furthermore, BAFF and APRIL have been shown to protect against drug induced cell 
death through upregulation of the pro-survival molecules BCL-2 and BCL-xL in B cell 
malignancy (10). These previous studies strengthen the case for the role of APRIL and 
BAFF in autoimmune disease and suggest that increased levels of these cytokines may be 
indicators of a poorer prognosis.  
The goal of this study was to determine if developmental B cell subsets express 
surface APRIL and BAFF and if this surface expression correlated with disease activity 
in RA and SLE patients. In this study, we assessed the surface expression of APRIL and 
BAFF and their receptors BAFF-R and TACI on circulating B cells and B cells subsets in 
RA and SLE patients compared to normal donors. In addition, we also assessed their 
association with disease activity in both RA and SLE. Our data show APRIL is expressed 
on total CD19+ and developmental B cell subsets in RA and SLE patients and positively 
correlates with DAS28 measurement of disease activity in RA patients. In addition 
surface BAFF is elevated on CD19+ and developmental B cell subsets in RA and SLE 
patients with highest expression found on CD27+ B cells in RA patients. BAFF-R is 
elevated on B cell subsets in RA patients and negatively correlates with disease activity 
in SLE patients. In both RA and SLE, TACI receptor was elevated on B cell subsets with 
the highest expression seen on transitional B cells. Elevated expression of BAFF-R and 
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TACI on transitional B cells suggests that these cells may be more responsive to APRIL 
and BAFF signaling. More studies are needed to determine the function of surface 
APRIL and BAFF in the B cell signaling pathways in RA and SLE, and how patients 
with elevated levels of surface APRIL and BAFF respond to targeted therapy by 
Belimumab and Atacicept. 
 
Materials And Methods 
Subjects 
 Subjects were enrolled in this study and gave informed consent under a protocol 
approved by the Loma Linda University (LLU) Institutional Review Board.  All RA and 
SLE patients were from Loma Linda University Division of Rheumatology Clinic, Loma 
Linda California or Beaver Medical Group Rheumatology Clinic, Redlands, CA USA. 
RA patients had a clinical diagnosis and met the 1987 American College of 
Rheumatology (ACR) criteria (23) and SLE patients met the 1997 ACR criteria for 
clinical diagnosis (24). Disease Activity Score out of 28 joints (DAS28) was used as a 
measure of RA disease activity (see Table 2). Systemic lupus erythematosus disease 
activity index (SLEDAI) was used to assess the disease activity in our SLE patient cohort 
(see Table 3.) The total patient population consisted of 18 RA patients and 10 SLE 
patients. Normal peripheral blood (PB) from anonymous adult donors was obtained from 
Leuko-pak leukocyte filters (Fenwal Laboratories, Lake Zurich, IL, USA), and donated 
by the Blood Processing and Quality Control Lifestream in San Bernardino, CA.   
 
Sample Preparation 
 Blood samples were collected in tubes containing acid citrate dextrose (ACD) 
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from Becton, Dickinson and Company (Franklin Lakes, NJ, USA).  Whole blood samples 
were centrifuged at 1500rpm for 15 minutes to remove plasma.  Peripheral blood 
mononuclear cells (PBMNCs) were then isolated by ammonium chloride lysis of red 
blood cells in both RA patient and normal PB samples.  
 
Flow Cytometry 
PBMNCs from RA, SLE, and normal donors were stained with mAbs in PBS for 
30 minutes in the dark at 4ºC. Cells were then washed with PBS and stained with Fixable 
Viability Dye eFluor® 450 (eBioscience) to distinguish between living and dead cells 
and incubated for 30 minutes at 4ºC in the dark. Cells were subsequently washed and 
fixed with a 1% paraformaldehyde solution before analysis using the MACSQuant® 
Analyzer (Miltenyi Biotec). The following isotype control antibodies were used: mouse 
IgG1 FITC, mouse IgG1 PE–Cy7 (eBioscience, San Diego, CA, USA); mouse IgG1 
APC-Cy7, rat IgG2b PerCP-Cy5.5 (Biolegend, San Diego, CA, USA); mouse IgG1 PE, 
mouse IgG1 APC (Miltenyl Biotech Inc., Auburn, CA, USA). The anti-human antibodies 
used were: CD256 PE (clone T3-6), CD21 FITC, TACI PE, CD24 PE-Cy7, CD27 APC-
Cy7 (Biolegend, San Diego, CA, USA); CD38 PE, IgM PE-Cy5 (BD Biosciences, San 
Jose, CA, USA); BAFF-R PE (eBioscience, San Diego, CA, USA); CD19 APC (Miltenyi 
Biotec); and Buffy-2 FITC (Abcam, Cambridge, Massachusetts, USA).  Compensation 
beads (anti-mouse Ig k compensation beads, BD Biosciences, San Jose, CA, USA) and 
cells stained with Fixable Viability Dye eFluor® 450 were used for machine 
compensation settings.  Flow cytometry alignment particles were used as an instrument 
settings control for each experiment (Sphero™ Ultra Rainbow Fluorescent Particles, 
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Lake Forest, IL, USA). Flow cytometry data analysis was performed using Flowjo data 
analysis software (TreeStar, Ashland, OR). 
 
Statistical Analysis 
Statistical differences were determined using non-parametric Mann-Whitney one-
tailed tests using GraphPad PRISM software (GraphPad, San Diego, CA, USA). 
Correlation analysis was performed using Spearman’s one-tailed test.  Differences were 
considered to be statistically significant for p<0.05. Grubb’s Test was used to exclude 
significant outliers. The mean and 95% confidence interval is shown in each graph.  
 
Results 
Identifying B cell Subsets in RA and  
SLE Patients and Normal Donors 
Multi-color flow cytometry was used to assess surface expression of members of 
the TNF Super Family (APRIL, BAFF, BAFF-R and TACI) on developmental B cell 
subsets identified based on the gating strategy shown for normal and RA PBMNCs 
staining (Figure 12A and 12B respectively). For flow cytometry analysis, intact 
peripheral blood mononuclear cells (PBMNCs) were gated based on forward (FSC) and 
side (SSC) light scatter (Figure 12A-B panel I). These cells were further gated to identify 
living cells (cells that were negative for viability dye, Figure 12A-B panels II). From 
intact living cells, lymphoid cells were identified based on size (indicated by FSC) and 
granularity (indicated by SSC) (gate shown in Fig.1A-B panel III).  B cells were 
identified based on CD19 expression (Figure 12A-B panel IV) and IgM expression was 
used to exclude B cell precursors and class-switched B cells (Figure 12A-B panel V).    
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The human memory B cell marker CD27 was used to distinguish between memory cells 
from non-memory B cells (Figure 12A-B panel VI). Non-memory B cells were further 
gated based on the co-expression of CD24 and CD38 to identify transitional and mature 
B cells subsets in human peripheral blood samples (Figure 12A-B panel VII) (25, 26).  
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Figure 12. Gating Strategy to Identify B cell Subsets in Normal and RA Peripheral 
Blood. PBMNC’s were stained for flow cytometry to identify B cell subsets in Normal 
(n=12), RA (n=16) and SLE (n=10) peripheral blood samples. Representative plots are 
shown for normal (A) and RA (B) PBMNCs. Forward (FSC) and side (SSC) light scatter 
were used to set a intact cell gate (panel I). From these, living (panel II) lymphoid cells 
(panel III) were gated. B cells were identified based on CD19+ expression (panel IV). A 
IgM+ cell gate was used to exclude B cell precursors and class-switched B cells (panel 
V).  Memory and non-memory B cells subsets were identified by CD27 expression as 
depicted by histogram (panel VI). CD24 and CD38 co-expression was used to identify 
transitional and mature B cell subsets (panel VII).  
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Surface APRIL is Elevated on B cell Subsets  
in RA and SLE Patients 
Surface APRIL expression has been identified on leukemic B cells, and is 
associated B cell survival due to its ability to protect B cells from chemotherapeutic 
induced apoptosis (19).  Our previous studies have shown that surface APRIL is also 
present on circulating monocytes subsets in RA patients and on non-classical monocytes 
in normal donors (A. Weldon, et al, Journal of Rheumatology, accepted.)  Therefore, we 
sought to determine if surface APRIL is expressed on developmental B cell subsets from 
patients with the B cell mediated autoimmune diseases--RA and SLE.  PBMNCs from 
RA and SLE patients were stained to identify B cell subsets as gated in Figure 12.   The 
median fluorescence intensity (MFI) of surface APRIL staining on gated B cell subsets  
(gated as shown in Figure 12A and B) from 12 normal donors, 16 RA and 10 SLE 
patients is shown in Figure 13A-E. Surface APRIL is elevated on total CD19+ B cells in 
both RA and SLE patients.  Next, we sought to determine which B cell subsets have 
surface APRIL expression.  Surface APRIL is elevated on memory (CD27+) and 
immature IgM+ B cells, and on transitional and mature B cells (identified by their CD24 
vs. CD38 expression patterns) in RA and SLE patients compared to normal donors. The 
highest level of APRIL expression was identified on transitional B cells (Figure 13D) in 
RA and SLE patients. These data indicate that surface APRIL is expressed on B cells 
from RA and SLE peripheral blood. 
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Figure 13. Surface APRIL is Elevated on B cells from RA and SLE Patients. 
Graphed is the median fluorescence intensity (MFI) of APRIL staining on CD19+ B cells 
(A), CD19+IgM+ B cells (B), and CD19+IgM+27+ memory B cells (C).  APRIL MFI on 
CD19+IgM+CD27- B cells using CD24 and CD38 co-expression patterns identified 
transitional B cells (D), and mature (E). Samples with insufficient cell numbers were 
excluded from the graph (D and F).  Statistical differences between RA and SLE patients 
and normal donors were determined by Mann-Whitney one-tailed test and differences 
were considered to be statistically significant for p<0.05. 
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Surface APRIL Expression Correlates 
 with Increased Disease Activity in RA 
Elevated levels of APRIL have been identified in the serum of SLE and RA 
patients, and in the synovial fluid of RA patients (8, 27-29). Increased serum levels of 
APRIL are associated with disease activity in SLE patients (16) and in juvenile idiopathic 
arthritis (30). RA patients with active disease have increased soluble APRIL levels (15). 
Recently, our own work showed that surface APRIL on myeloid cells correlates with 
disease activity in RA patients (A. Weldon, et al. J. Rheumatology, accepted). Here we 
evaluate the relationship between surface APRIL expression on total CD19+ B cells and 
disease activity in RA and SLE patients. The MFI for surface APRIL expression on total 
CD19+ B cells from RA patients (gated as shown in Figure 12B) was determined by flow 
cytometry.  Disease Activity Score in 28 joints (DAS28) found in Table 2, was used to 
determine the disease activity for each RA patient. The disease activity of our SLE 
patient cohort was determined by the SLE Disease Activity Index (SLEDAI) and is found 
in Table 3. In Figure 14, surface APRIL expression on CD19+ B cells shows a positive 
correlation with DAS28 score (r=0.4300 p=0.0486). Spearman’s rho analysis of surface 
APRIL expression on CD19+ B cells with disease activity in SLE patients yielded no 
correlation. This data shows that surface APRIL expression by CD19+ B cells in RA 
patients is associated with disease activity as indicated by DAS28 score. 
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Figure 14: Level of Surface APRIL on CD19+ B cells Correlates with Disease 
Activity in RA Patients. Surface APRIL expression (MFI) by CD19+ B cells from RA 
patients was determined by flow cytometry. The Spearman’s rho test indicates that 
surface APRIL expression on CD19+ B cells is correlated with disease activity as 
determined by DAS28 in n=16 RA patients. 
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Surface BAFF is Elevated on B cell Subsets  
in RA and SLE Patients 
 Naïve, memory, and plasma B cells from SLE patients with high disease activity 
have elevated surface BAFF expression compared to patients with low disease activity 
and healthy donors (18).  We sought to determine if surface BAFF expression was also 
elevated on RA B cells and to determine which B cells subsets express surface BAFF.  
Surface BAFF expression was determined by flow cytometry utilizing the Buffy-2 
monoclonal antibody that has been shown not to recognize receptor bound BAFF (9).  
RA and SLE patients had elevated levels of surface BAFF on all B cells subsets 
compared to normal donors (Figure 15 A-E). RA CD19+IgM+CD27+ memory B cells 
had the highest surface BAFF expression (Figure 15C).    
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Figure 15. Surface BAFF is Elevated on B cells from RA and SLE Patients. Graphed 
is the median fluorescence intensity (MFI) of BAFF staining on CD19+ B cells (A), 
CD19+IgM+ B cells (B), and CD19+IgM+27+ memory B cells (C).  BAFF expression 
on CD19+IgM+CD27- B cells using CD24 and CD38 co-expression patterns identified 
transitional B cells (D) and mature B cells (E). Samples with insufficient cell numbers 
were excluded from the graph (D and F).   Statistical differences between RA and SLE 
patients and normal donors were determined by Mann-Whitney one-tailed test and 
differences were considered to be statistically significant for p<0.05. 
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BAFF-R is Elevated on IgM+ B cells Subsets in RA Patients 
Decreased BAFF-R expression on CD19+ B cells from Chinese SLE patients has 
been shown (31). Due to this finding, we sought to determine the level of BAFF-R 
expression in our SLE patient cohort and in RA patients compared to normal donors. 
Living CD19+ B cells were gated in normal, RA, and SLE patient samples as shown in 
Figure 12.  Our data shows no difference in BAFF-R expression on total CD19+ B cells 
(Figure 16A).  However, BAFF-R is elevated on IgM+ B cells (Figure 15B), 
IgM+CD27+ memory B cells (Figure 16C), transitional (Figure 16D), and mature B cells 
(Figure 16E) from RA patients compared to healthy donors. No difference in BAFF-R 
expression was observed on any B cell subsets between our SLE patient cohort and 
normal donors. 
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Figure 16. BAFF-R is Elevated on IgM+ B cells from RA and SLE Patients. Graphed 
is the median fluorescence intensity (MFI) of BAFF-R staining on CD19+ B cells (A), 
CD19+IgM+ B cells (B), and CD19+IgM+27+ memory B cells (C).  BAFF-R expression 
on CD19+IgM+CD27- B cells using CD24 and CD38 co-expression patterns identified 
transitional B cells (D) and mature (E). Samples with insufficient cell numbers were 
excluded from the graph (D and F).   Statistical differences between RA and SLE patients 
and normal donors were determined by Mann-Whitney one-tailed test and differences 
were considered to be statistically significant for p<0.05. 
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BAFF Receptor Expression Negatively Correlates  
with Disease Activity in SLE Patients 
Previous reports have shown that CD19+ B cells negatively correlated with 
disease activity in SLE patients as determined by SLEDAI scores (31). The disease 
activity score for the SLE patients in this study are shown in Table 3. We did not observe 
a difference in SLE patient BAFF-R expression from our normal donors (Figure 16A), 
Our studies confirm previous reports, and show that BAFF-R MFI on total CD19+ B 
cells negatively correlates (r=-0.6874 and p=0.0250) with SLEDAI scores from our SLE 
patient cohort (see Figure 17).  In addition, BAFF-R MFI was also shown to negatively 
correlate (r=-0.4304 and p=0.0423) with BAFF MFI on CD19+ B cells from RA patients 
(data not shown). 
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Figure 17: BAFF-R Correlates with Disease Activity in SLE Patients. MFI values for 
BAFF-R expression on CD19+ B cells from SLE patients were determined and graphed 
in Figure 15A. The Spearman’s rho test indicates that BAFF-R expression on CD19+ B 
cells is negatively correlated with disease activity as determined by SLEDAI in n=8 SLE 
patients. 
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TACI Expression is Elevated on B Cells Subsets 
 in RA and SLE Patients 
TACI receptor has been shown to be elevated on SLE patients with active disease 
and the highest levels are seen on SLE patients with lupus nephritis (31). Living CD19+ 
B cells were gated in normal, RA, and SLE patient samples as shown in Figure 12. As 
seen in Figure 18A, no difference in TACI expression on total CD19+ B cells. In both 
RA and SLE patients, TACI is elevated on IgM+ B cells (Figure 16B), IgM+CD27+ 
memory B cells (Figure 18C), transitional (Figure 18D), and mature B cells (Figure 18E) 
compared to healthy donors.  Surface APRIL expression also positively correlated with 
TACI receptor expression on the same CD19+ B cells from RA patients (data not 
shown).  
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Figure 18. TACI Receptor is Elevated on IgM+ B cells from RA and SLE Patients. 
Graphed is the median fluorescence intensity (MFI) of TACI staining on CD19+ B cells 
(A), CD19+IgM+ B cells (B), and CD19+IgM+27+ memory B cells (C).  TACI 
expression on CD19+IgM+CD27- B cells using CD24 and CD38 co-expression patterns 
identified transitional B cells (D) and mature (E). Samples with insufficient cell numbers 
were excluded from the graph (D and F).   Statistical differences between RA and SLE 
patients and normal donors were determined by Mann-Whitney one-tailed test and 
differences were considered to be statistically significant for p<0.05. 
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Table 2: RA Patient Characteristics 
  
Sex 
(M/F 
Age 
(yrs.) 
Disease 
Duration 
(yrs) 
DAS28 
Score 
Rheumatoid 
Factor 
Treatment 
F 70 4 4.73 neg MTX, HCQ 
F 61 6 4.99 pos ADA, MTX 
M 46 1 3.7 pos LEF 
F 56 28 ND pos MTX, PRED 
F 21 3 4.35 pos NONE 
F 42 11 2.35 pos Etanercept 
F 68 10 ND ND MTX 
F 66 24 1.56 pos LEF 
F 64 5 2.35 pos MTX, HCQ 
F 56 29 5.13 pos MTX, PRED, LEF 
M 60 4 6.95 pos NONE 
F 57 15 1.53 pos MTX, Etanercept 
F 33 1 4.58 neg HCQ 
F 38 9 2.3 neg MTX, Rituximab 
F 64 6 2.8 neg MTX, HCQ 
F 62 1 2.72 pos MTX ,PDN  
F 75 15 3.57 ND MTX, Infliximab 
F 75 5 4.75 pos MTX  
 
NR: not reported, MTX: methotrexate, PRED: prednisone, LEF: leflunomide, HCQ: 
hydroxychloroquine, ADA: Adalimumab 
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Table 3: SLE Patient Characteristics  
 
Sex 
(M/F) 
Age 
(yrs.) 
Disease 
Duration 
(yrs) 
SLEDAI Treatment Clinical Features 
F 43 3 10 AZA, HCQ 
ANA, smith, anemia, 
thrombocytopenia 
F 48 35 2 MMF seizures, nephritis, rash, ANA 
F 35 9 NR HCQ 
ANA dsDNA, nephritis, arthritis, 
serositis 
F 32 10 NR HCQ nephritis, ANA 
F 24 8 2 
MMF, PRED, 
HCQ ANA dsDNA, rash, arthritis 
F 59 10 0 HCQ rash, alopecia, arthritis 
F 34 1 4 None alopecia, arthritis 
F 26 2 7 PDN  rash, oral ulcers, arthritis 
F 48 2 4 HCQ, PDN  arthritis, rash, alopecia 
F 64 4 2 AZA  alopecia, arthritis 
 
NR: not reported, PRED: prednisone, AZA: azathioprine, HCQ: hydroxychloroquine, 
MMF: mycophenolate mofetil 
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Discussion 
B cells have multiple roles in the pathogenesis or RA and SLE. The primary 
pathogenic function is the production and secretion of autoantibodies. B cell also serve as 
antigen-presenting cells (APCs) where they can activate T cells and secrete pro-
inflammatory cytokines (32, 33). B cell disturbances exist in both RA and SLE. Increased 
numbers of transitional, naïve mature, and CD27+ memory B cells have been measured 
in SLE patients (34). BAFF and APRIL and their receptors play important roles in these 
B cell mediated immune responses.  
The majority of functional studies of APRIL, BAFF and their receptors have been 
focused on the role of the soluble forms of APRIL and BAFF in the serum and synovial 
fluid. Recently surface forms of these molecules have been identified. Surface BAFF is 
expressed on leukemic B cells, and on naïve, memory, and plasma B cells from SLE 
patients with severe disease activity (18, 19). Surface forms of APRIL have been 
identified on cell lines from lymphoid and myeloid malignancies as well as macrophages 
in the synovial tissue of RA patients (19, 20, 22). Therefore, we sought to determine 
whether B cells and B cell subsets in RA and SLE PB express surface APRIL and BAFF.  
We show that RA and SLE patients have elevated surface APRIL and BAFF expression 
on total CD19+ and developmental B cell subsets (Figure 13 and 4). In addition, we show 
that surface APRIL expression on total CD19+ B cells positively correlates with disease 
activity in our RA patient cohort (Figure 14). 
Alterations in BAFF-R, which binds BAFF, and in TACI that binds both APRIL 
and BAFF have been reported in SLE patients. Previous studies report reduced BAFF-R 
expression on SLE B cells, which is negatively correlated with disease activity in SLE 
patients (31) and functional studies have shown that BAFF-R is decreased when exposed 
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to high levels of soluble BAFF (35).  This phenomenon may explain low levels of BAFF-
R staining shown in our SLE patient samples (Figure 16). However, RA patients had 
elevated levels of BAFF-R expression on IgM+, memory, transitional, and mature B cell 
subsets (Figure 16). We confirm previous reports that BAFF-R expression on CD19+ B 
cells negatively correlates with disease activity in SLE patients (Figure 17). Increased 
TACI receptor expression has been reported in patients with active SLE and with lupus 
nephritis (31). TACI is elevated on IgM+, memory, transitional, and mature B cell 
subsets (Figure 18) 
Alternative APRIL splice forms give rise to surface APRIL (36). BAFF is known 
to be cleaved at the cell surface; therefore, surface BAFF is a naturally occurring form of 
this protein (36). In contrast, APRIL is processed intracellularly within the Golgi 
apparatus and is then secreted from the cell (37). An intergenic splice form exists that is 
generated from the combination of exons 1-6 of TWEAK (a closely related TNF family 
member) and exons 2-6 of APRIL producing TWE-PRIL (38). TWE-PRIL has the 
transmembrane domain of TWEAK and the trimeric form of APRIL as an uncleaveable 
membrane bound protein (38). TWE-PRIL as well as alternative splice forms of APRIL 
may lead to the surface expression of APRIL seen in Figure 14 (36). The cells that 
express surface APRIL and its function in the pathology of rheumatic diseases has not 
been elucidated. In addition, it is not known whether the soluble and surface forms of 
APRIL have similar functions. The surface expression of APRIL in malignant cell lines 
suggests that this surface expression may be aberrant. Current work in our lab is 
investigating potential splice variants of APRIL not found in PBMNCs from normal 
donors.  
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The presence of elevated levels of APRIL and BAFF in the serum and synovial 
fluid of RA and SLE patients implicated these molecules as upstream mediators of B cell 
autoimmunity and led to the development of biologics to target these pathways (15, 16, 
28, 31). Recently, the FDA approved Belimumab for the treatment of autoantibody 
positive SLE for patients who do not respond to the standard of care therapy. Belimumab 
blocks BAFF from binding its receptors BAFF-R and TACI (39). The implication of 
APRIL in B-cell mediated autoimmune diseases led to the recent development of 
Atacicept, a humanized fusion protein of the Fc portion of IgG and TACI. Atacicept 
antagonizes APRIL as well as another cytokine, BAFF and is currently in Phase III 
clinical trials for the treatment of SLE (40). Since APRIL and BAFF have overlapping 
effects in B cell survival and maintenance, this drug provides promise in targeting 
multiple autoreactive B cell subsets including plasma cells. Atacicept may prove more 
effective in treating RA as it targets upstream inflammatory initiating events instead of 
blocking cytokines such as TNF-α. While these new drugs act on upstream inflammatory 
initiating events, determination of BAFF and APRIL levels are not a part of patient 
selection criteria for their administration, despite the diverse nature of these diseases. 
In conclusion, APRIL is expressed on total CD19+ and developmental B cell 
subsets in RA and SLE patients and positively correlates with DAS28 measurement of 
disease activity in RA patients. In addition, surface BAFF is elevated on CD19+ and 
developmental B cell subsets in RA and SLE patients with highest expression found on 
CD27+ B cells in RA patients. BAFF-R is elevated on B cell subsets in RA patients and 
negatively correlates with disease activity in SLE patients. In both RA and SLE, TACI 
receptor was elevated on B cell subsets with the highest expression seen on transitional B 
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cells. These results show that in SLE and in RA the patient’s B cells themselves serve as 
a reservoir of surface APRIL and BAFF that provides a potential source of stimulation 
for the BAFF-R and TACI receptors that are also upregulated on these cells. Elevated 
expression of BAFF-R and TACI on transitional B cells suggests that these cells may be 
more responsive to APRIL and BAFF signaling. More studies are needed to determine 
the function of surface APRIL and BAFF in the B cell signaling pathways in RA and 
SLE. 
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Abstract 
Introduction: Thymic stromal lymphopoietin (TSLP) is an IL-7 like cytokine that 
is produced by epithelial and stromal cells and is important in T and B cell development. 
TSLP has been associated with the pathogenesis of airway diseases such as asthma and is 
thought to cause the progression of cancer. Recent studies suggest that TSLP may also 
play a role in inflammatory arthritis by activating dendritic cells, which will ultimately 
lead to the activation of native T-cells and their differentiation into T help 2 (Th2) cells 
and the production of inflammatory cytokines such as TNF-a. In this study we evaluated 
TSLP in systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA), which are 
inflammatory B-cell mediated autoimmune diseases while osteoarthritis is considered to 
be non-inflammatory. By ELISA, we found elevated levels of TSLP in plasma from SLE 
patients and in synovial fluid of RA patients. The aim of this study is to compare of 
soluble TSLP from SLE and RA patients to non-inflammatory OA patients and determine 
the role of TSLP in RA and SLE.  
Methods: Peripheral blood (PB) and synovial fluid (SF) were collected from OA, 
RA, and SLE patients through an IRB-approved protocol. All patients were receiving 
treatment during the study. The TSLP levels in plasma and SF from patient samples were 
measured by ELISA using the Human TSLP ELISA MAX kit (Biolegend) according to 
the manufacture’s instructions. The minimum detection level of the ELISA was 3.9 
pg/mL.  The Mann and Whitney one-tailed U test was used to compare the TSLP 
concentration between patient groups. A P value of less than 0.05 was considered 
significant. 
Results: Plasma and SF samples obtained from OA, RA, and SLE patients were 
analyzed by ELISA. The TSLP levels in RA and SLE plasma and SF were compared to 
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OA samples. TSLP was elevated in plasma from SLE patients compared to OA 
(p=0.0276) and RA (p=0.007) plasma. RA SF had higher levels of TSLP than OA SF 
(p=0.0101).  
Conclusions: TSLP was elevated in SLE plasma at levels significantly higher than 
RA and OA plasma. This is the first study to show that TSLP is elevated in SLE patients. 
RA SF had higher levels of TSLP than OA SF confirming published reports. These data 
further implicate TSLP in inflammation within B-cell mediated autoimmune diseases. 
Ongoing studies are being focused on the role of TSLP in inflammation and correlation 
of TSLP with disease severity and treatment. 
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TSLP - Thymic Stromal Lymphopoietin 
IL – Interleukin 
IL-7Rα – Interleukin Seven Receptor Alpha Subunit 
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ELISA – Enzyme Linked Immunesorbent Assay 
PBMNCs - Peripheral Blood Mononuclear Cells 
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BAFF – B cell Activating Factor 
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Introduction 
Thymic stromal lymphopoietin (TSLP) is an IL-7 like cytokine that signals 
through the TSLP receptor (TSLP-R). This receptor consists of an IL-7 receptor alpha 
(IL-7Rα) subunit and a TSLP-R subunit and upon activation signals through the Jak-
STAT pathway in human cells. TSLP is primarily produced by epithelial cells in the skin, 
gastrointestinal tract, thymus, and lungs and by immune cells such as dendritic cells 
(DCs), mast cells, basophils, and fibroblasts (1-5). Several immune cells can respond to 
TSLP induced stimulation since TSLP-R is expressed on DCs, NK cells, mast cells, and 
T and B cells (6).  
TSLP may provide a link between the innate and adaptive immune system.  Toll-
like receptor (TLR) ligands induce the expression of TSLP in DC and monocytes (1).  
Upon activation these DCs produce pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 
through the activation of NF-κβ pathway. These DCs then act as antigen-presenting cells 
(APCs) to TSLP responsive immune cells such as CD4+ helper T cells and B cells (7). 
TSLP acts on DCs to differentiate native CD4+ T-cells into T helper 2 (Th2) cells, which 
produce pro-inflammatory cytokines such as TNF-α (8-10). TSLP also plays an 
important in T cell, B cell, and basophil development and homeostasis (11, 12).  
Increased levels of TSLP may lead to a breakdown of the normal immune cell 
homeostasis and contribute to the inflammatory processes in RA and other inflammatory 
autoimmune diseases. An overview of the cells targeted by TSLP and the inflammatory 
cytokines produced upon TSLP activation are shown in Figure 19. TSLP has been 
implicated in the pathogenesis of asthma, atopic dermatitis, systemic sclerosis, 
atherosclerosis, and cancer (4, 13-15).  In the collagen induced arthritis mouse model, 
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TSLP exacerbated their arthritis and these mice developed characteristics of a RA-like 
disease.  When these mice were treated with anti-TSLP monoclonal antibodies, a 
reduction in arthritis severity was observed suggesting that TSLP may play a role in the 
inflammatory arthritis in these animals (16).  More recently, TSLP has been implicated in 
the pathogenesis or RA since it is elevated in patients with RA; however, no association 
between TSLP and markers of inflammation and disease duration were found (16, 17). In 
RA patient synovial fluid (SF), TSLP was shown to be co-elevated with TNF-α. 
Moreover, RA synovial fibroblasts produce TSLP when treated with TNF-α suggesting a 
role for TSLP in the propagation of RA (16).   
Studies with RA patients have shown that TSLP is elevated in autoimmune 
disease characterized by autoantibody production. Systemic lupus erythematous (SLE) 
shares similar characteristics with RA, as these patients have numerous autoantibodies 
and elevated inflammatory cytokine production. In addition, both RA and SLE patients 
are often treated by the same therapeutics.  Therefore, the aim of this study was to 
compare the level of soluble TSLP from SLE and RA patients to non-inflammatory OA 
patients, and examine the role of TSLP in RA and SLE. By ELISA, we found elevated 
levels of TSLP in plasma from SLE patients and in synovial fluid of RA patients.  
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Figure 19. The Potential Role of TSLP in Inflammation. The cytokine TSLP is 
produced by stromal cells, DCs, and fibroblasts cells that line the synovium of joints.  
The TSLP receptor is expressed on multiple types of immune cells and its effects depend 
upon which cells it activates.  Studies have shown that TSLP exerts most of its effects on 
the DC interaction with naïve CD4+ T cells.  It induces their differentiation into Th2 
cells, which produce inflammatory cytokines such as TNF-α.  IN general, the effect of 
TSLP leads to an inflammatory response. 
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Materials and Methods 
Subjects 
 Subjects were enrolled in this study and gave informed consent under a protocol 
approved by the Loma Linda University (LLU) Institutional Review Board.  All RA, SLE 
and OA patients were from Loma Linda University Division of Rheumatology Clinic, 
Loma Linda California or Beaver Medical Group Rheumatology Clinic, Redlands, CA 
USA. All patients had a clinical diagnosis of RA and met the 1987 American College of 
Rheumatology criteria (18).  
 
Sample Preparation 
 Blood samples were collected by venipuncture in tubes containing acid citrate 
dextrose (ACD) from Becton, Dickinson and Company (Franklin Lakes, NJ, USA).  
Whole blood samples were centrifuged at 1500rpm for 15 minutes to remove plasma.  
The patient plasma was aliquoted and stored at -20C for future assays. Peripheral blood 
mononuclear cells (PBMNCs) were then isolated by ammonium chloride lysis of red 
blood cells in OA, RA and SLE patients and normal PB samples. All PBMNCs were 
stored in freezing media supplemented with 20% trehalose in liquid nitrogen. Synovial 
fluid was aspirated from the knee joint of OA and RA patients and stored at -20C for 
future assays. 
 
Soluble Cytokine Quantification 
Levels of TSLP in the plasma of OA, RA and SLE were determined by a 
sandwich ELISA (Human TSLP ELISA MAX Deluxe Kit, Biolegend San Diego, CA). 
Synovial fluid TSLP concentrations from OA and RA patients were also assessed by 
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ELISA without treatment with hyaluronidase.  ELISAs were performed according to 
manufacture’s instructions on freshly thawed plasma and synovial fluid. The ELISA 
plates were read at 450nm absorbance using the uQuant 96 well plate reader (Bio-Tek 
Instruments, Inc., Winooski, VT, USA). A standard curve was run in triplicate for each 
plate and samples were run in triplicate. TSLP plasma levels were calculated using a 4-
parameter logistic curve fit model in Bio-Tek software KCJunior V1.6 (Winooski, VT, 
USA). Samples with a coefficient of variability (%CV) greater than 15% were excluded. 
 
Flow Cytometry 
PBMNCs from RA, SLE, and OA donors were stained with mAbs in PBS for 30 
minutes in the dark at 4ºC. Cells were then washed with PBS and stained with Fixable 
Viability Dye eFluor® 450 (eBioscience) to distinguish between living and dead cells 
and incubated for 30 minutes at 4ºC in the dark. Cells were subsequently washed and 
fixed with a 1% paraformaldehyde solution before analysis using the MACSQuant® 
Analyzer (Miltenyi Biotec). The following isotype control antibodies were used: mouse 
IgG1 FITC, mouse IgG1 PE-Cy5, mouse IgG1 PE–Cy7 (eBioscience, San Diego, CA, 
USA); mouse IgG1 APC-Cy7, mouse IgG1 PerCP (Biolegend, San Diego, CA, USA); 
mouse IgG1 PE, mouse IgG1 APC (Miltenyl Biotech Inc., Auburn, CA, USA). The anti-
human antibodies used were: CD8 FITC, CD4 PE, CD56 FITC, CD19 FITC, and CD38 
PE (BD Biosciences, San Jose, CA, USA) and IgM PE-Cy5, CD24 PE-Cy7, TSLP-R 
APC, CD27 APC Cy7 (Biolegend, San Diego, CA, USA).  Compensation beads (anti-
mouse Ig k compensation beads, BD Biosciences, San Jose, CA, USA) and cells stained 
with Fixable Viability Dye eFluor® 450 were used for machine compensation settings. 
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Flow cytometry data analysis was performed using Flowjo data analysis software 
(TreeStar, Ashland, OR). 
 
Statistical Analysis 
Statistical differences were determined using non-parametric Mann-Whitney one-
tailed tests using GraphPad PRISM software (GraphPad, San Diego, CA, USA). 
Differences were considered to be statistically significant for p<0.05. Grubb’s Test was 
used to exclude significant outliers. The mean and 95% confidence interval is shown in 
each graph. The p values are provided in each figure. 
 
Results 
TSLP is Elevated in the Synovial Fluid of RA Patients 
TSLP has been shown to be elevated in the synovial fluid along with the 
inflammatory cytokine TNF-α and not in the synovial fluid of OA patients (16). More 
recently, elevated levels of TSLP in RA SF may play a role in activating myeloid DCs 
(19). Therefore, we sought to determine the levels of TSLP in the synovial fluid in our 
cohort of RA patients compared to non-inflammatory OA. Synovial fluid from the knee 
joint of both OA (n=6) and RA (n=13) patients was obtained and assessed by ELISA to 
determine the concentration of TSLP within the joint.  Our results are consistent with 
previous findings that the concentration of TSLP was significantly increased in the 
synovial fluid of RA patients compared to OA patients (Figure 20).    
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Figure 20. TSLP is Elevated in the Synovial Fluid of RA Patients. The concentration 
of TSLP in synovial fluid of RA (n=13) and OA (n=6) was determined by ELISA.  
Statistical differences between RA and OA patients were determined by Mann-Whitney 
one-tailed test and differences were considered to be statistically significant for p<0.05. 
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TSLP is Elevated in the Plasma of SLE Patients 
TSLP has been shown to be elevated locally in the joints of RA patients (16, 17). 
Next we sought to determine if TSLP was elevated in systemic autoimmune diseases RA 
and SLE compared to non-inflammatory OA.  The plasma levels of TSLP in RA (n=11), 
SLE (n=10) and OA (n=5) patients were analyzed by ELISA.  TSLP was elevated in the 
synovial fluid of RA patients (Figure 20), but no difference was observed between 
plasma levels of TSLP in RA and OA patient samples (Figure 21). However, we found 
that TSLP was significantly elevated in the plasma of SLE patients (Figure 22). This data 
suggests that TSLP may act locally in the joints of RA patients and systemically in SLE 
patients.  
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Figure 21. No Difference in TSLP Levels Were Observed Between RA and OA 
Patient Plasma. The concentration of TSLP in plasma of RA (n=11) and OA (n=5) was 
determined by ELISA.  Statistical differences between RA and OA patients were 
determined by Mann-Whitney one-tailed test and differences were considered to be 
statistically significant for p<0.05. 
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Figure 22. TSLP is Elevated in SLE Patient Plasma. The concentration of TSLP in 
plasma of SLE (n=10) and OA (n=5) was determined by ELISA.  Statistical differences 
between SLE and OA patients were determined by Mann-Whitney one-tailed test and 
differences were considered to be statistically significant for p<0.05. 
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Cellular Target of Increased TSLP Expression 
Next, we sought to determine the cellular target of this increased TSLP 
production. The TSLP-R expression on several immune cell populations was determined 
by flow cytometry. Myeloid DCs have been shown to have the high co-expression of 
TSLP-R and IL-7Rα (20). TSLP-R is also expressed on NK cells, mast cells, and T and B 
cells (6). Previous reports have shown that TSLP-R is elevated on Th2 cells as well (21). 
Therefore, we sought to determine the level of TSLP-R expression on these immune cell 
populations. The following immune cells were identified by cell surface markers: NK 
cells (CD56), DCs (CD11c), helper T cells (CD3 and CD4), cytotoxic T cells (CD3 and 
CD8), and immature and mature B cells subsets were identified based on the combination 
of CD19, CD27, IgM, CD38, and CD24.  Preliminary data from 2 independent 
experiments suggests that mature B cells (CD19+CD27-IgM+) from RA patients (n=3) 
have elevated levels of TSLP-R expression compared to normal donors.  We did not 
observe a difference between TSLP-R expression in T cell subsets, NK cells, and DCs 
within the PBMNCs of RA and SLE patients and normal donors. 
 
Discussion 
The role of TSLP in inflammation is an area of emerging investigation. RA and 
SLE are B cell mediated systemic autoimmune disease but also involve many other 
immune cells that participate in the inflammatory processes that lead to the homing of 
immune cells to the joint and the damage to the joint caused by these cells. While the 
exact pathways that lead to the development of RA and SLE are not known, genetic risk 
factors are known. Current theories hypothesize that these RA and SLE patients have a 
genetic risk of developing these diseases and when they encounter an environmental 
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exposure causing inflammation this leads to tissue damage and propagation of the disease 
by many immune cells (2-5).  TSLP may be a link between the normal maintenance of 
immune cells as well as their activation by environmental triggers through TLRs.  
Initiation of the pro-inflammatory effects of TSLP may be due to an 
environmental trigger such as a bacterial or viral infection through the involvement of 
TLRs in TSLP production. TSLP expression in mouse DCs and human monocytes is 
induced by TLR ligands zymosan (TLR2 ligand), LPS (TLR4 ligand), and CpG (TLR9 
ligand), which in turn increased the production of TSLP by DCs (1). TLR2, 3, 4, and 9 
ligands have been shown to induce TSLP promoted human DC activation leading to the 
production of cytokines known to initiate Th2 and Th17 activity in RA joints (1, 10, 19). 
In addition to Th2 cytokines, DCs produce CCL17 and CCL22 chemokines that induce 
the migration of immune cells (22). Both CCL17 and CCL22 are elevated in DCs from 
RA patients and are believed to lead to the homing of immune cells to the RA synovium 
(23, 24).  TSLP production by synovial fibroblast from RA patients was induced by 
TLR3 and 4 stimulation through a NF-κβ mediated mechanism (25). TLR stimulation of 
epithelial cells induced class switch recombination in B cells to enhance mucosal 
immunity.  This process is enhanced during TSLP promoted BAFF production by DCs 
(26). The ability of TSLP to activate DCs and synovial fibroblasts and lead to the 
production of inflammatory Th2 and Th17 cells and influence B cell antibody production 
suggests that this cytokine may provide a attractive target for therapeutics.  
TSLP may also serve as a chemokine as it can promote the migration of DC’s to 
areas of inflammation by serving as a messenger between the epithelia and innate 
immune cells (27).  Viral RNAs induce the production of TSLP in epithelial cells, a 
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major producer of TSLP (28). DCs treated with TSLP upregulate survival proteins, MHC 
class II and other co-stimulatory molecules enhancing their ability to interact and activate 
other immune cells involved in the pathogenesis of RA and SLE (2, 20). DCs from the 
synovium of RA patients show increased levels of co-stimulatory molecules with TSLP 
stimulation (7, 19). IL-32, a cytokine produced by upon cells during bacterial and viral 
infections, has been shown to be elevated in the synovium of RA patients. Recently, IL-
32 was shown to increase TSLP production in monocytes as well as their differentiation 
into macrophages, which are known to contribute to RA pathogenesis (29).  
TSLP supports the survival and differentiation of immune cells. TSLP promotes 
the development of basophils from bone marrow precursors (12). Murine immature IgM+ 
B cell development in bone marrow and fetal liver is supported by TSLP (30). TSLP 
plays a role in helper T cell survival and proliferation and the production of IL-4, IL-5 
and IL-13 (21). In the mouse, Th2 cells have higher levels of TSLP-R (21).  
Elevated levels of TSLP have been examined in RA, however no studies have 
expanded to include similar systemic autoimmune conditions such as SLE. TSLP the 
synovial fluid of RA joints showed co-elevation with a known inflammatory cytokine 
TNF-α differing from another study that showed no correlation between synovial levels 
of TSLP and TNF-α (16, 19). In our study, we show that TSLP is elevated in the synovial 
fluid of RA but not OA patients (Figure 20). In addition, we are the first to show that 
TSLP is elevated in the plasma of SLE patient when compared to RA and OA patients 
(Figure 21-4). These data suggest that TSLP may act locally in the joints of RA patients 
and systemically in SLE patients. Ongoing studies will explore the role of systemically 
elevated TSLP in the pathogenesis of SLE. 
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Therapeutics that are currently being used to treat patients with RA and SLE have 
an impact of the levels of TSLP. Glucocorticoids, immune suppressives often used to 
treat systemic autoimmune disorders, have been shown to inhibit TSLP potentially 
through blocking the NF-κβ activation (31). In RA mouse models, treatment with anti-
TSLP monoclonal antibodies significantly reduced the arthritis score in these animals 
(16). In RA patients, TSLP levels were significantly lower in patients that were treated 
with DMARDS and TNF-α inhibitors (19). Therefore, targeting TLSP either directly 
with monoclonal antibodies or indirectly by preventing NF-κβ activation through the use 
of glucocorticoids may prove beneficial in treating the inflammatory events in asthma, 
dermatitis, arthritis, and lupus. 
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CHAPTER FIVE 
DISCUSSION 
The success of biological therapies in the treatment of RA has dramatically 
improved the management of this disease and other autoimmune disorders. Newly 
developed biologics have the potential to selectively target immune components involved 
in autoimmune disease. The TNF antagonists are an example of targeted therapy and 
have shown great promise in the treatment of RA and SLE. However, due to the 
heterogeneous nature of these diseases, the response to these drugs is suboptimal in 30-
40% of patients (1-5). Therefore, identifying subsets of patients based on their surface 
and soluble biomarkers and identifying which therapeutics that will provide the most 
benefit for these patient cohorts has the potential to rationalize the treatment of RA and 
SLE patients.  
 
Identification of Patient Cohorts and Therapeutic Response 
through Genome Wide Association Studies 
RA is a complex and heterogeneous disease that has contributions from lymphoid, 
myeloid and fibroblast cells with in the joint. The use of genome-wide expression 
analysis (GWAS) has recently been used to identify to major forms of RA—lymphoid 
and myeloid that contribute to the inflammation in the RA synovium (6). In addition, 
GWAS studies have identified two main pathways in the pathogenesis that involve TLR 
signaling and type I interferon signaling (7). Pharmacogenetic studies have great potential 
to assist in predicting which therapies would be more effective in each type of RA and 
SLE. This type of big data approach may be the future of personalized medicine in which 
 124 
your genetic profile will be used to determine genetic susceptibility to disease and 
therapeutic effectiveness. 
 
TSLP and APRIL Induced IgA Antibody Production by Mucosal 
B Cells 
Intestinal epithelial cells (IECs) play a role in mucosal immunity by secreting 
TSLP that can signal through TSLP-R on mDCs in the intestine. These TSLP induced 
DCs promote the differentiation of CD4+ Th cells into Th2 effect T cells (8). These 
TSLP DCs produce BAFF and APRIL and TLR5 induced IECs produced APRIL, which 
bind the TACI receptor on mucosal B cells resulting in T cell independent class switch 
recombination to produce IgA antibodies (9, 10).  This provides a link between the 
microbiome and mucosal immunity.  
 
Viruses as the Environmental Trigger in RA and SLE 
Viral infections may serve as environmental triggers for the development of 
autoimmune disease.  Type I interferon is produced by numerous immune cells as a 
response to viral infections. The combination of type I interferon and immune complex 
ligation of TLR7 or 9 can lead to the activation of pDCs.  Activated DCs present self-
antigens to B cells leading to their differentiation to plasma cells (11). Viruses can also 
induce TLR mediated epithelial cell production of BAFF (12). The increased levels of 
BAFF may allow autoreactive B cells to escape negative selection resulting in circulating 
autoreactive B cells.  BAFF can also augment the APRIL induced IgA antibody 
production (10). Non-classical monocytes patrol the vasculature respond to viruses 
through TLR7 and 8 and produce TNF-α and IL-1β (13). The collaboration of these 
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immune cells and cytokines implicate a viral environmental trigger in RA and SLE 
patients with elevated levels of APRIL, BAFF and TSLP. 
 
Identification of RA and SLE Biomarkers and Determination of 
Their Relationship to Disease Activity  
The aim of our studies was to identify easily detectable biomarkers in RA and 
SLE patients and provide insight into the role of these biomarkers in the pathology of B 
cell mediated autoimmune diseases. 
 
Surface APRIL as a Biomarker in RA 
The cytokine APRIL has been implicated as a potential disease mediator in B cell 
mediated autoimmune diseases (14). APRIL is elevated in the serum and synovial fluid of 
RA patients (15, 16). While multiple immune cells secrete APRIL, it is also expressed on 
the surface of myeloid leukemia cell lines and macrophages in RA synovium (17-22). 
The expression of surface APRIL by monocyte subsets in normal individuals and its 
relationship to RA are unknown. In this study, we sought to compare surface APRIL 
expression on circulating myeloid cells in both normal and autoimmune patients, and to 
determine whether expression of surface APRIL is related to plasma levels of soluble 
APRIL and disease activity in RA patients.   
Our studies are the first to show that surface APRIL is expressed on circulating 
myeloid cells in RA patients (Figure 5) and that levels of surface APRIL are highly 
correlated with disease activity (Figure 7). Monocytes can be divided into 3 distinct 
subsets based on the co-expression of CD14 and CD16 (23). Pro-inflammatory non-
classical monocytes have previously been shown to be elevated in RA patients with 
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active disease (13, 24). We show that both non-classical (CD14loCD16+) and 
intermediate (CD14+CD16+) monocyte subsets are increased in RA patients (Fig. 8B) 
indicating the pool of monocytes in RA patients is skewed toward pro-inflammatory 
monocyte subsets. Examination of surface APRIL expression on circulating monocyte 
subsets showed low levels of surface APRIL on intermediate monocytes, and high levels 
of surface APRIL on non-classical monocytes in normal donors (Fig. 9D). In contrast, 
surface APRIL was expressed at high levels on all monocyte subsets in RA patients (Fig. 
9E). Our findings suggest that surface APRIL could provide an easily detectable 
biomarker and be a useful selection criterion for the administration of Atacicept. Surface 
APRIL expression, together with monocyte subset skewing, might provide a prognostic 
indicator of RA patient response to Atacicept or other drugs that target APRIL (25). 
 
The Potential for the Use of Surface Expression of APRIL, BAFF and 
Their Receptors as Biomarkers in RA and SLE 
APRIL and BAFF and their receptor TACI are elevated in early RA. This 
suggests that using the combined expression of APRIL, BAFF and the receptors BAFF-R 
and TACI (seen in Figure 4) could provide a biomarker panel for the diagnosis of RA and 
SLE patients. In addition, the expression patterns of APRIL and BAFF could provide a 
rationale for the use of Belimumab and Atacicept in RA and SLE patients. Flow 
cytometry was used to assess the surface expression of APRIL, BAFF, BAFF-R and 
TACI on total CD19+ B cells and B cell subsets, and if this surface expression correlated 
with disease activity in established RA and SLE patients.   
 Surface APRIL was expressed on total CD19+ and developmental B cell subsets 
in RA and SLE patients and positively correlated with disease activity in RA patients 
 127 
(Figure 13-14). Surface BAFF was elevated on CD19+ and developmental B cell subsets 
in RA and SLE patients with the highest expression found on CD27+ memory B cells in 
RA patients (Figure 15). BAFF-R was elevated on B cell subsets in RA patients and 
negatively correlated with disease activity in SLE patients (Figure 16-17). In both RA 
and SLE, TACI receptor was elevated on B cell subsets with the highest expression 
identified on transitional B cells (Figure 18). The elevated expression of surface APRIL 
and BAFF on B cell subsets in established RA and SLE patients suggest that these 
cytokines may serve as potential biomarkers for the identification of RA and SLE.  
Further testing is needed to determine how patients with elevated levels of surface 
APRIL and BAFF respond to targeted therapy by Belimumab and Atacicept. 
 
The Potential for the Use of TSLP as a Systemic Biomarker in SLE 
and Local Biomarker in RA Patients 
TSLP is an IL-7 like cytokine that is produced by epithelial and stromal cells and 
is important in T and B cell development. Recently, TSLP has been implicated in the 
pathogenesis of RA as it is elevated in RA patients and enhances an RA-like phenotype 
in mouse models of RA (26, 27). Moreover, RA synovial fibroblasts produce TSLP when 
treated with TNF-α suggesting a role for TSLP in the propagation of RA(26). The aim of 
our study was to compare the level of soluble TSLP from SLE and RA patients to non-
inflammatory OA patients, and examine the role of TSLP in RA and SLE. TSLP was 
elevated in the synovial fluid of RA but not OA patients (Figure 20). In addition, we are 
the first to show that TSLP is elevated in the plasma of SLE patient when compared to 
RA and OA patients (Figure 21-22). These data suggest that TSLP may act locally in the 
joints of RA patients and systemically in SLE patients. Future studies will need to 
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determine the role of systemically elevated TSLP and the immune cell signaling 
pathways induced by TSLP in SLE.  
 
Conclusions 
The studies described in Chapters 2-4 examine biological relevant biomarkers to 
identify RA and SLE patients and the potential use of the expression patterns of these 
cytokines in providing a rationale to guide treatment strategies that target APRIL and 
BAFF.  In addition, our study also implicates the cytokine TSLP in SLE pathogenesis. 
Targeting this cytokine may be useful in the treatment of RA and SLE patients and 
therapeutics aimed at targeting TSLP are currently under development (28). 
  
Future Directions 
Alternative splicing gives rise to APRIL isoforms that may lead to the surface 
expression of APRIL. It is not known whether alternative splice or another mechanism 
results in the surface expression of APRIL. Future studies will identify APRIL isoforms 
in RA and SLE PBMNCs. Preliminary studies have shown that a subset of our RA and 
SLE patients express APRIL splice variants. It is also unclear whether surface APRIL can 
generate pro-survival signals that are produced by soluble APRIL and whether drugs that 
antagonize APRIL will be effective in patients with elevated surface APRIL expression. 
More studies are needed to determine the function of surface APRIL and BAFF in the B 
cell signaling pathways in RA and SLE, and how patients with elevated levels of surface 
APRIL and BAFF respond to targeted therapy by Belimumab and Atacicept.  
TSLP is elevated in the joint of RA patients and systemically in SLE patients. The 
role of these elevated TSLP levels in immune response in RA and SLE patients is unclear 
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as studies in asthma show a skewing toward a Th2 response and a Th17 response in RA 
patients. Future studies will focus on the role of TSLP in inflammation and correlation of 
TSLP with disease activity in RA and SLE and identify therapeutics that will be effective 
in treating the subset of patients with elevated TSLP. These studies will provide a 
rationale for the use of APRIL and TSLP as biomarkers in RA and SLE. 
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